Lazard Asset Management Adds TMT Long/Short Equity Team

Lazard Asset Management Adds TMT Long/Short Equity Team

– Firm expands alternative investment platform with new absolute return strategy –

NEW YORK–(BUSINESS WIRE)–
Lazard Asset Management LLC (“LAM”) today announced the expansion of its alternative investment platform, with the addition of a long/short equity team focused on the technology, media, and telecommunications (TMT) industries. Co-Portfolio Managers Thomas Wang and Charles Murias are joining LAM from HM Global Management, where they have had a proven track record of investing together in the TMT space.

“We are pleased to welcome Thomas and Charles to Lazard,” said Loren Katzovitz, Managing Director, who leads the expansion of LAM’s alternative investment platform. “We believe their industry expertise and proven investment process will enhance our absolute return-focused platform.”

As Co-Portfolio Managers of the newly formed LAM TMT team, Mr. Wang and Mr. Murias will continue to manage their long/short equity strategy, focused on the Global TMT Sector. The strategy, which they have managed since inception, is based on a fundamental, research-driven process. It is style-agnostic and unconstrained, with the primary objective of maximizing alpha and risk-adjusted returns.

“We are looking forward to joining Lazard. Having the ability to leverage LAM’s research capabilities, technology, risk management, operational infrastructure, and global distribution, will not only enhance our fundamental research capabilities, but will also enable us to spend the majority of our time doing what we love – investing,” said Mr. Wang.

As of March 31, 2021, Lazard’s Alternative Investment Platform managed approximately $3.1 billion in client assets.

About Lazard Asset Management (LAM) LLC

An indirect subsidiary of Lazard Ltd (NYSE: LAZ), LAM offers a range of equity, fixed-income, and alternative investment products worldwide. As of March 31, 2021, LAM and affiliated asset management companies in the Lazard Group managed $264.9 billion worth of client assets. For more information about LAM, please visit www.LazardAssetManagement.com. Follow LAM at @LazardAsset.

AM- LAZ

Hillary Yaffe, +1 212 632 6528

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 2021 at 8:00 a.m. ET

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

Dial-in Number

U.S./Canada Dial-in Number: 800-527-6973
International Dial-in Number: 470-495-9162
Conference ID: 5767008

Replay Dial-in Number: 855-859-2056
Replay International Dial-in Number: 404-537-3406
Conference ID: 5767008

An audio webcast will be accessible through the Investor Relations section of the company’s website https://ir.fulcrumtx.com/events-and-presentations. Following the live webcast, an archived replay will also be available.

About Fulcrum Therapeutics 
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

Please visit www.fulcrumtx.com.

Contact:

Christi Waarich
Director, Investor Relations and
Corporate Communications
617-651-8664
[email protected]



Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin

Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin

FY 2021 Annual Revenue of $848 Million, Up 1%, with 27.1% Operating Margin during COVID-19 pandemic

DANVERS, Mass.–(BUSINESS WIRE)–
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record fourth quarter fiscal 2021 revenue of $241.2 million compared to revenue of $206.7 million for the same period of fiscal 2020, driven by a record number of patients supported. For fiscal year 2021, total revenue was $847.5 million, up 1% compared to revenue of $840.9 million, and operating income was $229.6 million compared to operating income of $249.2 million in fiscal year 2020.

Recent financial and operating highlights include:

  • Worldwide Impella® heart pump revenue for the quarter totaled $230.4 million, an increase of 17% compared to revenue of $197.4 million during the same period of the prior fiscal year. Full year worldwide Impella heart pump revenue totaled $806.3 million for fiscal 2021, compared to revenue of $806.8 million for fiscal 2020.
  • U.S. Impella product revenue for the quarter totaled $186.1 million, an increase of 13% compared to revenue of $164.0 million during the same period of the prior fiscal year with U.S. patient usage of the Impella heart pumps up 13%. Full year U.S. Impella revenue totaled $655.2 million, down 3% compared to $674.4 million in the prior fiscal year.
  • Outside the U.S., Impella product revenue for the quarter totaled $44.3 million, an increase of 33% compared to revenue of $33.4 million during the same period of the prior fiscal year. Full year Impella product revenue outside the U.S. totaled $151.1 million, an increase of 14% compared to $132.4 million in the prior fiscal year. Japan revenue was $11.6 million for the quarter and $42.9 million for the year, up 38% and 22%, respectively, compared to prior fiscal year.
  • Gross margin for the fourth quarter of fiscal 2021 was 80.9%, flat compared to the same period of fiscal 2020. For the full fiscal year 2021, gross margin was also 80.9% compared to 82.0% in fiscal year 2020.
  • Operating income for the fourth quarter fiscal 2021 was $62.8 million, or 26.0% operating margin, compared to $58.1 million, or 28.1% operating margin in the same period of fiscal 2020, due to incremental growth investments and stock-based compensation. For the full fiscal year 2021, operating income was $229.6 million, or 27.1% of revenue, compared to $249.2 million, or 29.6% of revenue in the prior fiscal year.
  • Fourth quarter fiscal 2021 GAAP net income was $56.9 million, or $1.24 per diluted share, which includes a $5.9 million, or $0.13 per diluted share, unrealized gain on our investment in Shockwave. This compared to GAAP net income of $31.8 million, or $0.70 per diluted share for the prior fiscal year, which included a $13.6 million, or $0.30 per diluted share, unrealized loss on our investment in Shockwave.
  • Full fiscal year 2021 GAAP net income was $225.5 million, or $4.94 per diluted share, which includes a $38.4 million, or $0.84 per diluted share, unrealized gain on our investment in Shockwave and $12.1 million, or $0.26 per diluted share, of excess tax benefits related to employee share-based compensation awards. This compared to GAAP net income was $203.0 million, or $4.43 per diluted share for the prior fiscal year.
  • The company generated operating cash flow of $86.5 million in the fourth quarter and $274.6 million for the full fiscal year 2021. As of March 31, 2021, the company had $847.8 million of cash and marketable securities and no debt.
  • On January 29, the company announced results from a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers which found a 79% survival rate at explant. A majority of surviving patients recovered their native heart function without needing further mechanical support or a heart transplant. The study was presented at The Society of Thoracic Surgeons (STS) 2021 Annual Meeting by lead author Edward Soltesz, MD, MPH, a cardiovascular and heart transplant surgeon at Cleveland Clinic’s Miller Family Heart, Vascular & Thoracic Institute.
  • On February 17, the company announced the appointment of Myron Rolle, MD, to the Abiomed Board of Directors, effective immediately. Dr. Rolle will serve as a member of the Governance and Nominating Committee and Regulatory and Compliance Committee of the board. Dr. Rolle is a neurosurgeon, Rhodes scholar, and former professional football player in the National Football League.
  • On April 15, the company announced that the first patient has been enrolled in PROTECT IV, a large, prospective, on-label, multi-center randomized controlled trial (RCT) that is designed to provide the level of clinical evidence needed to achieve a Class I guideline recommendation1 for Impella in high-risk percutaneous coronary intervention (HRPCI). The first patient was enrolled at Ascension St. John Hospital in Detroit by Dr. Ted Schreiber and Dr. Amir Kaki.
  • On April 28, the company announced the appointment of Paula Johnson, MD, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Dr. Johnson is a cardiologist and the 14th president of Wellesley College. Previously, she was the founder and inaugural executive director of the Connors Center for Women’s Health and Gender Biology and was chief of the Division of Women’s Health at Brigham and Women’s Hospital in Boston.
  • On April 28, the company announced the final results from the National Cardiogenic Shock Initiative (NCSI), a single-arm, prospective study assessing outcomes associated with early mechanical circulatory support (MCS) in acute myocardial infarction cardiogenic shock (AMICS) patients treated with PCI. The study evaluated the outcomes of 406 consecutive patients who presented with AMICS from 80 sites throughout the United States, demonstrating a 71% survival to discharge with greater than 90% native heart recovery, when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI).

“At Abiomed, our Patients First mindset gives us purpose and courage and we always seek opportunities to lead, manage, adapt and execute,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “For this fiscal year, I would like to thank our employees and customers for their courage, dedication to patients and leadership throughout the pandemic. We exited the year slightly up in revenue, profitable and stronger than ever before.”

FISCAL YEAR 2022 OUTLOOK

The company anticipates fiscal year 2022 global revenue to be in the range of $990 million to $1,030 million, representing 17% to 22% growth compared to fiscal year 2021 The company is also giving its fiscal year 2022 guidance for GAAP operating margin to be in the range of 24% to 26%. The company plans to give another formal forecast for the fiscal year on our next earnings call.

EARNINGS CONFERENCE CALL DETAILS

The company will host a conference call to discuss the quarterly and full year results at 8:00 a.m. ET on Thursday, April 29, 2021. The conference call will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd A. Trapp, Vice President and Chief Financial Officer.

To listen to the call live, please tune into the webcast via https://edge.media-server.com/mmc/p/u4c589ep or dial (855) 212-2361; the international number is (678) 809-1538. A replay of this conference call will be available beginning at 11:00 a.m. ET April 29, 2021 through 11:00 a.m. ET on May 6, 2021. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 9899023.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System are pending trademarks of Abiomed, Inc.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed’s existing and new products, the company’s progress toward commercial growth, and future opportunities and expected regulatory approvals. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company’s filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

 

Abiomed, Inc. and Subsidiaries

 

Consolidated Balance Sheets

 

(Unaudited)

 

(in thousands, except share data)

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2021

 

 

March 31, 2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

232,710

 

 

$

192,341

 

Short-term marketable securities

 

 

350,985

 

 

 

250,775

 

Accounts receivable, net

 

 

97,179

 

 

 

84,650

 

Inventories

 

 

81,059

 

 

 

90,088

 

Prepaid expenses and other current assets

 

 

26,032

 

 

 

18,009

 

Total current assets

 

 

787,965

 

 

 

635,863

 

Long-term marketable securities

 

 

264,085

 

 

 

207,795

 

Property and equipment, net

 

 

197,129

 

 

 

164,931

 

Goodwill

 

 

78,568

 

 

 

31,969

 

Other intangibles, net

 

 

42,150

 

 

 

14,913

 

Deferred tax assets

 

 

11,380

 

 

 

43,336

 

Other assets

 

 

113,082

 

 

 

117,655

 

Total assets

 

$

1,494,359

 

 

$

1,216,462

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

34,842

 

 

$

32,774

 

Accrued expenses

 

 

66,046

 

 

 

75,107

 

Deferred revenue

 

 

24,322

 

 

 

19,147

 

Other current liabilities

 

 

3,759

 

 

 

4,857

 

Total current liabilities

 

 

128,969

 

 

 

131,885

 

Other long-term liabilities

 

 

10,162

 

 

 

9,305

 

Contingent consideration

 

 

24,706

 

 

 

9,000

 

Deferred tax liabilities

 

 

847

 

 

 

806

 

Total liabilities

 

 

164,684

 

 

 

150,996

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Class B Preferred Stock, $.01 par value

 

 

 

 

 

 

Authorized – 1,000,000 shares; Issued and outstanding – none

 

 

 

 

 

 

 

 

Common stock, $.01 par value

 

 

453

 

 

 

451

 

Authorized – 100,000,000 shares; Issued 47,929,402 shares as of March 31, 2021 and 47,542,061 shares as of March 31, 2020

 

 

 

 

 

 

 

 

Outstanding 45,270,948 shares as of March 31, 2021 and 45,008,687 shares as of March 31, 2020

 

 

 

 

 

 

 

 

Additional paid in capital

 

 

800,690

 

 

 

739,133

 

Retained earnings

 

 

828,007

 

 

 

602,482

 

Treasury stock at cost 2,658,454 shares as of March 31, 2021 and 2,533,374 shares as of March 31, 2020

 

 

(288,030

)

 

 

(265,411

)

Accumulated other comprehensive loss

 

 

(11,445

)

 

 

(11,189

)

Total stockholders’ equity

 

 

1,329,675

 

 

 

1,065,466

 

Total liabilities and stockholders’ equity

 

 

1,494,359

 

 

 

1,216,462

 

 

Abiomed, Inc. and Subsidiaries

 

Consolidated Statements of Operations

 

(Unaudited)

 

(in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

Fiscal Years Ended March 31,

 

 

2021

 

2020

 

 

2021

 

2020

 

Revenue

$

241,246

 

$

206,658

 

 

$

847,522

 

$

840,883

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

46,078

 

 

39,369

 

 

 

161,907

 

 

151,305

 

Research and development

 

31,989

 

 

25,346

 

 

 

121,875

 

 

98,759

 

Selling, general and administrative

 

100,375

 

 

83,891

 

 

 

334,183

 

 

341,600

 

 

 

178,442

 

 

148,606

 

 

 

617,965

 

 

591,664

 

Income from operations

 

62,804

 

 

58,052

 

 

 

229,557

 

 

249,219

 

Other income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment income, net

 

1,049

 

 

3,100

 

 

 

6,717

 

 

12,167

 

Other income (expense), net

 

9,641

 

 

(21,839

)

 

 

51,946

 

 

(4,561

)

 

 

10,690

 

 

(18,739

)

 

 

58,663

 

 

7,606

 

Income before income taxes

 

73,494

 

 

39,313

 

 

 

288,220

 

 

256,825

 

Income tax provision

 

16,638

 

 

7,515

 

 

 

62,695

 

 

53,816

 

Net income (A)

$

56,856

 

$

31,798

 

 

$

225,525

 

$

203,009

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

$

1.26

 

$

0.71

 

 

$

5.00

 

$

4.49

 

Basic weighted average shares outstanding

 

45,246

 

 

45,040

 

 

 

45,140

 

 

45,179

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income per share (B)

$

1.24

 

$

0.70

 

 

$

4.94

 

$

4.43

 

Diluted weighted average shares outstanding

 

45,783

 

 

45,575

 

 

 

45,674

 

 

45,816

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(A) Net income includes the effect of the following items:

 

 

 

 

 

 

 

 

 

 

 

 

 

Excess tax benefits related to stock-based compensation awards

 

(1,708

)

 

(1,063

)

 

 

(12,071

)

 

(14,838

)

Unrealized (gain) loss on investment in Shockwave Medical – net of tax

 

(5,946

)

 

13,595

 

 

 

(38,379

)

 

367

 

 

$

(7,654

)

$

12,532

 

 

$

(50,450

)

$

(14,471

)

(B) Diluted net income per share includes the effect of the following items:

 

 

 

 

 

 

 

 

 

 

 

 

 

Excess tax benefits related to stock-based compensation awards

 

(0.04

)

 

(0.02

)

 

 

(0.26

)

 

(0.32

)

Unrealized (gain) loss on investment in Shockwave Medical – net of tax

 

(0.13

)

 

0.30

 

 

 

(0.84

)

 

0.01

 

 

$

(0.17

)

$

0.28

 

 

$

(1.10

)

$

(0.31

)

______________________________________

1 Class I recommendations are strong and indicate that the treatment, procedure, or intervention is useful and effective and should be performed or administered for most patients under most circumstances. Halperin, J. et al., (2015). Circulation, 133:1426–1428

 

Todd Trapp

Vice President and Chief Financial Officer

978-646-1680

[email protected]

Sarah Lima

Communications Manager

978-882-8211

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: General Health Health Cardiology Medical Devices

MEDIA:

Logo
Logo

GRAVITY ANNOUNCES FILING OF ANNUAL REPORT ON FORM 20-F FOR FISCAL YEAR 2020

Seoul, April 29, 2021 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or the “Company”) today announced that the Company filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the Securities and Exchange Commission on April 29, 2021. The annual report can be accessed on the Company’s investor relations Web site at http://www.gravity.co.kr/en/ir/notice/list.asp

The shareholders and ADS holders of Gravity may receive a hard copy of the annual report, which contains its audited consolidated financial statements, free of charge upon request. Requests should be directed to IR Unit, Gravity Co., Ltd., 15F, 396 World Cup buk-ro, Mapo-gu, Seoul 03925, South Korea.

In the annual report on Form 20-F, the consolidated revenue is KRW 405,953 million, the operating profit is KRW 88,368 million, and the net profit attributable to parent company is KRW 62,703 million for the fiscal year ended December 31, 2020.

(In millions of KRW)

  2020 2019 YoY
Revenue 405,953 360,967 12.5%
Operating profit 88,368 48,663 81.6%
Net profit attributable to parent company 62,703 39,876 57.2%

About GRAVITY Co., Ltd. —————————————————
Based in Korea, Gravity is a developer and publisher of online and mobile games. Gravity’s principal product, Ragnarok Online, is a popular online game in many markets, including Japan and Taiwan, and is currently commercially offered in 93 markets and countries. For more information about Gravity, please visit http://www.gravity.co.kr.

Contact:
Mr. Heung Gon Kim
Chief Financial Officer
Gravity Co., Ltd.
Email: [email protected]

Ms. Jin Lee
Ms. Hyeji An
IR Unit
Gravity Co., Ltd.
Email: [email protected]
Telephone: +82-2-2132-7800



EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

Study Initiates with Registration on ClinicalTrials.gov

MENLO PARK, Calif.–(BUSINESS WIRE)–
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of initiating the Company’s EXPAND Clinical Study by successfully registering on ClinicalTrials.gov (NCT04858802). EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States. The EXPAND study’s primary objective is to evaluate the efficacy of the Company’s PROPEL® Contour (mometasone furoate) sinus implant when placed in the frontal sinus ostium following in-office balloon dilation in patients with chronic rhinosinusitis (CRS) as compared to balloon sinus dilation alone. Patients will be assessed at various intervals throughout the study with a final follow up at 6 months.

Consistent with the Company’s strategic initiative to drive more procedural growth into the office site of care, the EXPAND trial will focus on the clinical benefits of the PROPEL Contour implant in reducing inflammation and maintaining patency following sinus surgery when used in combination with balloon sinus dilation in patients suffering from CRS. There are approximately 150,000 balloon sinus dilation procedures performed annually in the United States with a substantial number of these procedures treating the frontal sinus ostia in ENT surgeons’ offices. In addition to near-term study claims, positive EXPAND results could also provide a pathway for the Company to consider additional clinical studies demonstrating the durability of outcomes to support label expansion and the collection of valuable health economic evidence for the use of PROPEL Contour in conjunction with balloon sinus dilation procedures.

“In our PROPEL Contour PROGRESS trial we observed a cohort of patients that received balloon dilation and PROPEL Contour resulting in a larger frontal sinus ostia opening versus the control group without PROPEL at day 30,” states Thomas A. West, President and CEO of Intersect ENT. “With the launch of our VenSure® sinus balloon following the acquisition of Fiagon AG, we would like to expand the number of patients examined and further solidify the benefit of PROPEL Contour post-sinus balloon dilation.” The Company anticipates enrollment to begin in the EXPAND trial in May 2021 and targets completion of enrollment by year-end with results in 2022.

The PROPEL Contour Steroid Releasing Sinus Implant

The PROPEL Contour sinus implant is intended to maintain patency of the frontal and maxillary sinus ostia and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

About Intersect ENT®

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus dilation balloon, that complement the Company’s PROPEL® and SINUVA® sinus implants and extend its geographic reach.

For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL® (mometasone furoate) sinus implants, please visit www.PROPELOPENS.com.

Intersect ENT®, PROPEL® and are registered trademarks of Intersect ENT, Inc.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We may, in some cases, use terms such as “look forward,” confident,” “promises,” “predicts,” “believe,” “potential,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Intersect ENT’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation those related to the safety, efficacy and patient and physician adoption of the Company’s products and therapies, the ability to obtain and maintain reimbursement codes for its products, the Company’s ability to procure and maintain required regulatory approvals for our products, the Company’s ability to grow and expand its business, as well as other risks detailed from time to time in Intersect ENT’s filings with the Securities and Exchange Commission (SEC), including Intersect ENT’s filings on Form 10-K and Form 10-Q available at the SEC’s Internet site (www.sec.gov). Intersect ENT does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Source: Intersect ENT, Inc.

IR Contact:

Randy Meier, 650-641-2105

Executive Vice-President & CFO

[email protected]

Media Contact:

Erich Sandoval, 917-497-2867

Finn Partners for Intersect ENT

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Science Biotechnology Research Pharmaceutical Surgery Health Medical Devices Clinical Trials

MEDIA:

Logo
Logo

Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients

Topline results are expected in the first quarter of 2022

BLACKSBURG, Va., April 29, 2021 (GLOBE NEWSWIRE) — Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that the Company dosed the first patient in a Phase 1b study of NX-13 for ulcerative colitis (UC). NX-13 is Landos’ potentially first-in-class, novel, orally administered, gut-restricted NLRX1 agonist for the treatment of UC and Crohn’s disease (CD).

“UC is a chronic and debilitating disease that impairs the quality of life of millions of patients worldwide, with many relapsing in less than a year after receiving currently available therapies. Our novel oral product candidate, NX-13, is designed to initiate a robust multimodal mechanism and restore immune tolerance in patients with UC, both as a single agent or in combination with other therapeutics,” commented Josep Bassaganya-Riera, Ph.D., Chairman, President, and CEO of Landos Biopharma. “Our rapid advancement of NX-13 to a Phase 1b trial in just over a year is supportive of our differentiated approach to target the NLRX1 pathway, which can favorably modulate epithelial barrier integrity and interactions with the gut microbiome, while decreasing reactive oxygen species formation and inflammation in the GI tract. As our second first-in-class product candidate to enter the clinic, NX-13 is quickly progressing through clinical development in UC and will soon enter clinical testing for CD as well as for other autoimmune diseases.”

The Phase 1b study is a randomized, placebo-controlled, double-blind, multicenter, dose ranging study, evaluating 40 subjects with active UC over 28 days. All subjects will be randomized to receive one of the three NX-13 treatment regimens: 250 mg immediate release tablets (IR), 500 mg IR, 500 mg modified release tablets (MR) or placebo. The objective of the trial will be to evaluate the safety and pharmacokinetics of multiple dose levels of NX-13 in patients. Exploratory biomarkers of response to treatment, including fecal calprotectin, will also be evaluated. In March, Landos announced successful completion of a Phase 1a study of NX-13 in normal healthy volunteers, which identified a maximum tolerated dose 10-fold greater than the anticipated therapeutic dose, validated the gut-restricted profile of NX-13, and demonstrated a preliminary signal of response in reduction of fecal calprotectin levels.

“After clearing 5 investigational new drug applications with the FDA and with three clinical trials completed, a Phase 2 trial for omilancor about to be initiated in CD, in addition to the Phase 1b trial of NX-13 in UC patients, we continue to accelerate the clinical development of our top product candidates in our expansive therapeutic pipeline. We expect to quickly report topline data for this Phase 1b trial of NX-13 in the first quarter of 2022,” said Jyoti Chauhan, EVP of Operations & Regulatory Affairs of Landos Biopharma.

About Ulcerative Colitis (UC)

UC is a chronic, autoimmune, inflammatory bowel disease that causes inflammation, irritation, and ulcers in the lining of the large intestine (colon) and rectum. Symptoms include abdominal pain, rectal pain and bleeding, bloody stools, diarrhea, fever, weight loss, and malnutrition. Having UC puts a patient at increased risk of developing colon cancer. Diagnosis typically occurs in early adulthood and the disease requires maintenance treatment for the remainder of the patient’s life. UC is estimated to affect over 900,000 patients in the United States and over 1 million patients throughout the rest of the world. With 70% of addressable patients experiencing a second flare within one year and 30% of patients in remission failing to stay in remission for more than one year, there is an unmet medical need in UC for safer and more efficacious therapeutics.

About NX-13

NX-13 is a first-in-class, orally-active, gut-restricted, small molecule therapeutic candidate for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD). NX-13 targets NLRX1, a mitochondria-associated receptor with the ability to modulate immune responses. By activating the NLRX1 pathway, NX-13 increases autophagy and oxidative phosphorylation in immune cells while decreasing differentiation of effector CD4+ T cells, reactive oxygen species, inflammasome formation and production of inflammatory cytokines. The Company reported positive results from the Phase 1a study of NX-13 in healthy volunteers in Q1 2021 and initiated a Phase 1b study of NX-13 in patients with ulcerative colitis in Q2 2021.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit www.landosbiopharma.com.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Landos Biopharma, Inc. (the “Company”), including statements about the Company’s strategy, clinical development of the company’s therapeutic candidates, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “subject to”, “believe”, “anticipate”, “plan”, “expect”, “intend”, “estimate”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s product candidates and other similar risks. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Contacts:

Michael K. Levitan (investors)
Solebury Trout
646-378-2920
[email protected]

Hannah Gendel (media)
Solebury Trout
646-378-2943
[email protected] 

 



The Eclipse Foundation Unveils its New Vision for Managing and Operating Edge Computing Environments via Open Source Software

EdgeOps adapts DevOps methodologies for distributed environments and the Intelligent Edge

BRUSSELS, Belgium, April 29, 2021 (GLOBE NEWSWIRE) — The Eclipse Foundation, one of the world’s largest open source software foundations, as well as the Edge Native Working Group, today announced the release of a new white paper entitled “EdgeOps: A New Vision For Edge Computing” The paper articulates a new approach for building software solutions for edge computing environments, with an emphasis on open source. EdgeOps is an adaptation of DevOps, with a focus on software, tooling and processes for edge computing environments. It specifically addresses the challenges of edge computing, such as power, security, latency, communication protocols, etc., and takes into account the characteristics of edge computing solutions and associated deployment approaches required in an edge environment. The white paper is available now as a free download.

“Despite the meteoric rise of edge computing, there remains a great deal of confusion on precisely where the ‘edge’ begins and ends. It has also been a struggle for the industry to define best practices for managing traditional IT infrastructure versus remote or edge-based operational technology (OT) assets,” said Mike Milinkovich, executive director of the Eclipse Foundation. “This white paper is an important step in articulating the challenges and opportunities relative to the new OT ecosystem and in demonstrating the power of open source collaboration for building real solutions that can be leveraged across a broad range of industries.”

Edge computing architectures provide enterprises, manufacturers, cloud providers, telcos, and many other organizations with significant benefits in terms of performance, cost, resiliency, data sovereignty and security. These benefits often come with increased complexity and new challenges for developers. Heterogeneous hardware, multiple forms of network connectivity, mobility requirements, power issues, environmental conditions such as temperature and weather, as well as physical security are all unique to edge environments. The EdgeOps concept means the use of agile teams of specialists to solve each of these challenges.

The Eclipse Foundation has been a key enabler of EdgeOps through a number of projects hosted by the Edge Native Working Group, including three of the most innovative projects within the EdgeOps ecosystem: Eclipse ioFog, Eclipse zenoh, and Eclipse fog05. The ioFog project is a commercial-grade production-ready open source platform that was recently honored with the 2020 IoT Edge Computing Excellence Award by IoT Evolution World. This award recognizes organizations and products that enable advanced IoT deployments by bringing real-time computing, data availability, analytics, AI and machine learning to edge devices.

Developers, architects and others interested in learning more can download “EdgeOps – A New Vision for Edge Computing.” The Eclipse Foundation will participate in KubeCon + CloudNativeCon Europe May 4-7, 2021. Visit us in the Silver Hall to see all the latest Eclipse Foundation developments.

To learn more about getting involved with the Eclipse Edge Native Working Group, please visit us at https://edgenative.eclipse.org/, or email us at [email protected]. Individually, developers can join the Edge Native mailing list where the Eclipse Foundation shares working group progress.

About the Eclipse Foundation

The Eclipse Foundation provides our global community of individuals and organizations with a mature, scalable, and business-friendly environment for open source software collaboration and innovation. The Foundation is home to the Eclipse IDE, Jakarta EE, and over 375 open source projects, including runtimes, tools, and frameworks for cloud and edge applications, IoT, AI, automotive, systems engineering, distributed ledger technologies, open processor designs, and many others. The Eclipse Foundation is a rapidly growing international non-profit association supported by over 300 members, including more than 90 new members added in 2020 alone. These members represent a diverse collection of industry leaders that value open source technology as a key enabler for their business strategies. To learn more, follow us on Twitter @EclipseFdn, LinkedIn or visit eclipse.org.

Third-party trademarks mentioned are the property of their respective owners.

Media contacts    

Nichols Communications for the Eclipse Foundation

Jay Nichols
[email protected]
+1 408-772-1551



Newmont Delivers Solid First Quarter 2021 Results

Newmont Delivers Solid First Quarter 2021 Results

On track to meet full-year guidance with solid first quarter results; Newmont continues to invest in the Company’s future and diverse world-class portfolio

DENVER–(BUSINESS WIRE)–
Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or the Company) today announced first quarter 2021 results.

FIRST QUARTER 2021 HIGHLIGHTS

  • Produced 1.5 million attributable ounces of gold and 317 thousand attributable gold equivalent ounces from co-products
  • Reported gold CAS* of $752 per ounce and AISC* of $1,039 per ounce
  • Generated $841 million of cash from continuing operations and $442 million of Free Cash Flow (99 percent attributable to Newmont)*
  • Full-year production continues to be back-half weighted, in line with 2021 guidance**
  • Declared first quarter dividend of $0.55 per share, consistent with the previous quarter***
  • Ended the quarter with $5.5 billion of consolidated cash and $8.5 billion of liquidity with a net debt to adjusted EBITDA* ratio of 0.2x
  • Reduced $550 million of debt outstanding with available cash in April 2021
  • Executed $3.0B sustainability-linked revolving credit facility, demonstrating Newmont’s unwavering commitment to industry-leading environmental, social and governance (ESG) practices
  • First production from Boddington Autonomous Haulage System, delivering safety and productivity improvements; leading the way as the industry’s first autonomous haulage fleet
  • Announced acquisition of GT Gold,+ located in the prospective Golden Triangle adding profitable copper and gold exposure to Newmont’s industry-leading project portfolio
  • Continued focus on fatality prevention through global application of critical controls

“In the first quarter we delivered a solid financial performance with $1.5 billion in adjusted EBITDA and $442 million in free cash flow, putting Newmont on track to achieve our full-year guidance with improving production expected in the second half of the year. We remain confident in the strength of our business as we invest in our world-class portfolio, strengthening the balance sheet and sustaining our quarterly dividend of $0.55 per share,” said Tom Palmer, President and Chief Executive Officer. “We remain focused on proactively eliminating risks that could lead to a fatality and continue to lead the industry with our safety and sustainability practices. We believe that strong ESG performance is a key indicator of a well-managed business and we continue to hold ourselves accountable to create value and improve lives through sustainable and responsible mining.”

– Tom Palmer, President and Chief Executive Officer

________________________________________________

*Non-GAAP metrics; see footnotes at the end of this release.

**See cautionary statement at end of release regarding forward-looking statements.

***See the cautionary statement at the end of this release, including with respect to future dividends.

+The GT Gold transaction is expected to close in the second quarter of 2021, subject to meeting normal closing conditions. See the Company’s news release, dated March 10, 2021, for additional information.

FIRST QUARTER 2021 FINANCIAL AND PRODUCTION SUMMARY

 

Q1’21

Q1’20

Q4’20

Attributable gold production (million ounces)

1.46

 

1.48

 

1.63

 

Gold costs applicable to sales (CAS) ($ per ounce)

$

752

 

$

781

 

$

739

 

Gold all-in sustaining costs (AISC) ($ per ounce)

$

1,039

 

$

1,030

 

$

1,043

 

GAAP Net income (US $ millions)

$

538

 

$

837

 

$

806

 

Adjusted net income (US $ millions)

$

594

 

$

326

 

$

856

 

Adjusted EBITDA (US $ millions)

$

1,457

 

$

1,118

 

$

1,772

 

Cash flow from continuing operations (US $ millions)

$

841

 

$

939

 

$

1,686

 

Capital Expenditures (US $ millions)

$

399

 

$

328

 

$

398

 

Free cash flow (US $ millions)

$

442

 

$

611

 

$

1,288

 

Attributable gold production1 was in line compared to the prior year quarter, decreasing 2 percent to 1,455 thousand ounces primarily due to the sale of Red Lake, lower leach pad production and the ramp down of the mill at Yanacocha, lower mill throughput at Nevada Gold Mines, lower ore grade milled at Merian and lower production at Cerro Negro as the site focuses on returning operations to full capacity while managing ongoing Covid-related impacts. These decreases were largely offset by higher ore grade milled at Peñasquito, Musselwhite, Boddington and Akyem.

Gold CAS2 improved 7 percent to $1,065 million from the prior year quarter primarily due to lower ounces sold. Gold CAS per ounce improved 4 percent to $752 per ounce primarily due to higher by-product credits from higher realized metal prices and lower stockpile and leach-pad inventory adjustments, partially offset by higher gold price-driven royalties and lower ounces sold.

Gold AISC3 remained flat compared to the prior year quarter at $1,039 per ounce as higher sustaining capital spend and higher advanced projects spend were largely offset by lower CAS per ounce.

Attributable gold equivalent ounce (GEO) production from other metals decreased 6 percent to 317 thousand ounces primarily due to lower ore grade milled at Peñasquito, partially offset by higher grade and throughput at Boddington.

CAS from other metals totaled $182 million for the quarter. CAS per GEO2 improved 8 percent to $555 per ounce from the prior year quarter primarily due to a lower allocation of costs to other metals and higher sales at Peñasquito, partially offset by unfavorable foreign currency impacts from the strengthening of the Australian dollar and higher copper price-driven royalties at Boddington. AISC per GEO3 improved 5 percent to $819 per ounce primarily due to lower CAS from other metals, partially offset by higher sustaining capital spend.

Net income from continuing operations attributable to Newmont stockholders was $538 million or $0.67 per diluted share, a decrease of $299 million from the prior year quarter primarily due to the recognized gains on the sales of Kalgoorlie, Red Lake and investment holdings in Continental Gold, Inc. (Continental) in the prior year, higher income tax expense and lower sales volumes in the current year. These decreases were partially offset by higher average realized prices in the current year, the impairment charge of TMAC Resources, Inc. (TMAC) in the prior year and charges from debt extinguishment in the prior year.

Adjusted net income4was $594 million or $0.74 per diluted share,compared to $326 million or $0.40 per diluted share in the prior year quarter. Primary adjustments to first quarter net income include changes in the fair value of investments, gains on asset and investment sales, reclamation and remediation charges and valuation allowance and other tax adjustments.

Adjusted EBITDA5 improved 30 percent to $1,457 million for the quarter, compared to $1,118 million for the prior year quarter.

Revenue increased11 percent from the prior year quarter to $2,872 million primarily due to higher average realized metal prices, partially offset by lower sales volumes.

Average realized price6 for gold was $1,751, an increase of $160 per ounce over the prior year quarter. Average realized gold price includes $1,780 per ounce of gross price received, the unfavorable impact of $20 per ounce mark-to-market on provisionally-priced sales and reductions of $9 per ounce for treatment and refining charges.

Capital expenditures7 increased 22 percent from the prior year quarter to $399 million primarily due to higher sustaining capital spend from Boddington Autonomous Haulage and higher development capital spend. Development capital expenditures in 2021 primarily include advancing Tanami Expansion 2, Yanacocha Sulfides, Cerro Negro expansion projects, Ahafo North, the Subika Mining Method Change, Quecher Main and projects associated with the Company’s ownership interest in Nevada Gold Mines.

Consolidated operating cash flow from continuing operations decreased 10 percent from the prior year quarter to $841 million primarily due to higher tax payments and other net unfavorable working capital movements , partially offset by higher average realized metal prices. Free Cash Flow8alsodecreased to $442 million primarily due to lower operating cash flow and higher capital expenditures as described above.

Balance sheet ended the quarter with $5.5 billion of consolidated cash and approximately $8.5 billion of liquidity; reported net debt to adjusted EBITDA of 0.2x9.

Nevada Gold Mines (NGM) attributable gold production was 303 thousand ounces with CAS of $745 per ounce and AISC of $868 per ounce for the first quarter. EBITDA10 for NGM was $294 million.

Pueblo Viejo (PV) attributable gold production was 91 thousand ounces for the quarter. Pueblo Viejo EBITDA10 was $117 million and cash distributions received for the Company’s equity method investment totaled $38 million in the first quarter.

COVID-19 UPDATE

Newmont continues to maintain wide-ranging protective measures for its workforce and neighboring communities, including screening, physical distancing, deep cleaning and avoiding exposure for at-risk individuals. The Company incurred incremental Covid specific costs of $22 million during the quarter for activities such as additional health and safety procedures, increased transportation and community fund contributions. During the second quarter of 2020, the Newmont Global Community Support Fund was established to help host communities, governments and employees combat the Covid pandemic. Amounts distributed from this fund were $1 million during the quarter and have been adjusted from certain non-GAAP metrics. The remaining $21 million is not adjusted from our non-GAAP metrics.

We have mobilized a Covid vaccine working group with representatives from across the globe. Newmont views vaccination as critical in the fight against Covid-19 and actively encourages our workforce to get vaccinated as they become eligible. We are working to support authorities, through our Global Community Support Fund, to improve the availability and deployment of vaccines to our workforce and host communities.

PROJECTS UPDATE

Newmont’s capital-efficient project pipeline supports improving production, lowering costs and extending mine life. Funding for the current development capital project Tanami Expansion 2 has been approved and the project is in execution stage. The Company has included the Ahafo North and Yanacocha Sulfides projects in its long-term outlook as the projects are scheduled to be approved for full funding in 2021. Additional sustaining and development projects, not listed below, represent incremental improvements to the Company’s outlook.

  • Tanami Expansion 2 (Australia) secures Tanami’s future as a long-life, low-cost producer with potential to extend mine life beyond 2040 through the addition of a 1,460 meter hoisting shaft and supporting infrastructure to achieve 3.5 million tonnes per year of production and provide a platform for future growth. The expansion is expected to increase average annual gold production by approximately 150,000 to 200,000 ounces per year for the first five years and is expected to reduce operating costs by approximately 10 percent. Capital costs for the project are estimated to be between $850 million and $950 million with a commercial production date in the first half of 2024.
  • Ahafo North (Africa) expands our existing footprint in Ghana with four open pit mines and a stand-alone mill located approximately 30 kilometers from the Company’s Ahafo South operations. An investment decision is expected in July 2021 and the project is expected to add 300,000 ounces per year with all-in sustaining costs between $600 to $700 per ounce for the first five full years of production (2024-2028), with estimated capital costs of between $700 and $800 million. Ahafo North is the best unmined gold deposit in West Africa with approximately 3.5 million ounces of Reserves and more than 1 million ounces of Measured and Indicated and Inferred Resource11 and significant upside potential to extend beyond Ahafo North’s current 13-year mine life.
  • Yanacocha Sulfides (South America)12 will develop the first phase of sulfide deposits and an integrated processing circuit, including an autoclave to process gold, copper and silver feedstock. The project is expected to add 500,000 gold equivalent ounces per year with all-in sustaining costs between $700 to $800 per ounce for the first five full years of production (2026-2030). An investment decision is expected in the second half of 2021 with a three year development period and estimated capital costs of approximately $2 billion. The first phase focuses on developing the Yanacocha Verde and Chaquicocha deposits to extend Yanacocha’s operations beyond 2040 with second and third phases having the potential to extend life for multiple decades.

________________________________________________

1 Attributable gold production for the first quarter 2021 includes 91 thousand ounces from the Company’s equity method investment in Pueblo Viejo (40%).

2Non-GAAP measure. See end of this release for reconciliation to Costs applicable to sales.

3 Non-GAAP measure. See end of this release for reconciliation to Costs applicable to sales.

4 Non-GAAP measure. See end of this release for reconciliation to Net income (loss) attributable to Newmont stockholders.

5 Non-GAAP measure. See end of this release for reconciliation to Net income (loss) attributable to Newmont stockholders.

6 Non-GAAP measure. See end of this release for reconciliation to Sales.

7 Capital expenditures refers to Additions to property plant and mine development from the Condensed Consolidated Statements of Cash Flows.

8 Non-GAAP measure. See end of this release for reconciliation to Net cash provided by operating activities.

9 Non-GAAP measure. See end of this release for reconciliation.

10 Non-GAAP measure. See end of this release for reconciliation.

11See note to U.S. Investors at the end of this release; such resource estimate for Ahafo North is comprised of 610,000 ounces of Measured and Indicated Resource and 410,000 ounces of Inferred Resource as at December 31, 2020.

12 Consolidated basis.

OUTLOOK

Newmont’s outlook reflects increasing gold production and ongoing investment in its operating assets and most promising growth prospects. The Company has included Ahafo North and Yanacocha Sulfides in its outlook as the development projects are expected to reach execution stage in 2021. Additional development projects that have not reached execution stage represent upside to guidance. All production, cost and capital figures assume a $1,200/oz gold price.

Newmont’s 2021 and longer-term outlook assumes operations continue without major Covid-related interruptions. If at any point the Company determines that continuing operations poses an increased risk to our workforce or host communities, it will reduce operational activities up to, and including, care and maintenance and management of critical environmental systems. Please see cautionary statement in the end notes for additional information.

For a more detailed discussion, see the Company’s 2021 and Longer-Term Outlook released on December 8, 2020, available on www.newmont.com.

Five Year Cost and Production Outlook (+/- 5%)

Guidance metric

2021E

2022E

2023E

2024E

2025E

Gold Production* (Moz)

6.5

6.2 – 6.7

6.2 – 6.7

6.5 – 7.0

6.5 – 7.0

Other Metal Production** (Mozs)

1.3

1.2 – 1.4

1.4 – 1.6

1.4 – 1.6

1.4 – 1.6

Total GEO Production (Mozs)

7.8

7.5 – 8.0

7.7 – 8.2

8.0 – 8.5

8.0 – 8.5

CAS*** ($/oz)

$750

$650 – $750

$625 – $725

$600 – $700

$600 – $700

All-in Sustaining Costs*** ($/oz)

$970

$850 – $950

$825 – $925

$800 – $900

$800 – $900

Sustaining Capital* ($M)

$950

$900 – $1,100

$900 – $1,100

$900 – $1,100

$900 – $1,100

Development Capital* ($M)

$850

$1,000 – $1,200

$900 – $1,100

$200 – $400

$100 – $300

Total Capital* ($M)

$1,800

$2,000 – $2,200

$1,900 – $2,100

$1,200 – $1,400

$1,100 – $1,300

*Attributable basis; **Attributable co-product gold equivalent ounces; includes copper, zinc, silver and lead; ***Consolidated basis for gold

2021 Regional Outlooka

2021 Outlook (+/-5%)

Consolidated Production (Koz, GEOs Koz)

Attributable Production (Koz, GEOs Koz)

Consolidated CAS ($/oz)

Consolidated All-In Sustaining Costs b ($/oz)

Consolidated Sustaining Capital Expenditures ($M)

Consolidated Development Capital Expenditures ($M)

Attributable Sustaining Capital Expenditures ($M)

Attributable Development Capital Expenditures ($M)

North America

1,760

 

1,760

 

730

 

915

 

300

 

25

 

300

 

25

 

South America

1,000

 

1,075

 

850

 

1,035

 

125

 

200

 

100

 

150

 

Australia

1,330

 

1,330

 

650

 

860

 

235

 

400

 

235

 

400

 

Africa

915

 

915

 

715

 

900

 

115

 

160

 

115

 

160

 

Nevada Gold Minesc

1,370

 

1,370

 

760

 

960

 

210

 

130

 

210

 

130

 

Total Gold

6,400

 

6,500d

 

750

 

970

 

1,000e

 

900

 

950e

 

850

 

 

 

 

 

 

 

 

 

 

Total Co-productsf

1,300

 

1,300

 

600

 

880

 

 

 

 

 

2021 Consolidated Expense Outlook ($M) (+/-5%)

General & Administrative

260

Interest Expense

275

Depreciation and Amortization

2,500

Exploration & Advanced Projects

390

Adjusted Tax Rate g,h

34%-38%

Federal Tax Rate h

27%-30%

Mining Tax Rate h

6%-9%

a 2021 regional outlook projections used in this presentation are considered forward-looking statements and represent management’s good faith estimates or expectations of future production results as of December 8, 2020. Outlook is based upon certain assumptions, including, but not limited to, metal prices, oil prices, certain exchange rates and other assumptions. For example, 2021 Outlook assumes $1,200/oz Au, $22/oz Ag, $2.75/lb Cu, $1.05/lb Zn, $0.90/lb Pb, $0.75 USD/AUD exchange rate, $0.77 USD/CAD exchange rate and $50/barrel WTI; AISC and CAS estimates do not include inflation, for the remainder of the year. Production, CAS, AISC and capital estimates exclude projects that have not yet been approved, except for Ahafo North and Yanacocha Sulfides which are included in Outlook as the development projects are expected to reach execution stage in 2021. The potential impact on inventory valuation as a result of lower prices, input costs, and project decisions are not included as part of this Outlook. Assumptions used for purposes of Outlook may prove to be incorrect and actual results may differ from those anticipated, including variation beyond a +/-5% range. Outlook cannot be guaranteed. As such, investors are cautioned not to place undue reliance upon Outlook and forward-looking statements as there can be no assurance that the plans, assumptions or expectations upon which they are placed will occur. Amounts may not recalculate to totals due to rounding. See cautionary at the end of this release.

b All-in sustaining costs or AISC as used in the Company’s Outlook is a non-GAAP metric; see below for further information and reconciliation to consolidated 2021 CAS outlook.

c Represents the ownership interest in the Nevada Gold Mines (NGM) joint venture. NGM is owned 38.5% by Newmont and owned 61.5% and operated by Barrick. The Company accounts for its interest in NGM using the proportionate consolidation method, thereby recognizing its pro-rata share of the assets, liabilities and operations of NGM. Production, CAS and AISC for the Company’s 38.5% ownership interest in NGM as provided by Barrick Gold Corporation based on a $1,200/oz gold price assumption.

d Attributable gold production outlook includes the Company’s equity investment (40%) in Pueblo Viejo with ~325Koz in 2021; does not include the Company’s other equity investments. Attributable gold production outlook represents the Company’s 51.35% interest for Yanacocha and a 75% interest for Merian.

e Total sustaining capital includes ~$20 million of corporate and other spend.

f Gold equivalent ounces (GEO) is calculated as pounds or ounces produced multiplied by the ratio of the other metal’s price to the gold price, using Gold ($1,200/oz.), Copper ($2.75/lb.), Silver ($22/oz.), Lead ($0.90/lb.), and Zinc ($1.05/lb.) pricing.

g The adjusted tax rate excludes certain items such as tax valuation allowance adjustments.

h Assuming average prices of $1,500 per ounce for gold, $22 per ounce for silver, $2.75 per pound for copper, $0.90 per pound for lead, and $1.05 per pound for zinc and achievement of current production and sales volumes and cost estimates, we estimate our consolidated adjusted effective tax rate related to continuing operations for 2021 will be between 34%-38%.

 

Three Months Ended March 31,

Operating Results

2021

2020

% Change

Attributable Sales (koz)

 

 

 

Attributable gold ounces sold (1)

1,361

 

1,369

 

(1

)%

Attributable gold equivalent ounces sold

327

 

319

 

3

%

 

 

 

 

Average Realized Price ($/oz, $/lb)

 

 

 

Average realized gold price

$

1,751

 

$

1,591

 

10

%

Average realized copper price

$

4.20

 

$

1.56

 

169

%

Average realized silver price

$

19.73

 

$

14.13

 

40

%

Average realized lead price

$

0.88

 

$

0.64

 

38

%

Average realized zinc price

$

1.06

 

$

0.62

 

71

%

 

 

 

 

Attributable Production (koz)

 

 

 

North America

413

 

376

 

10

%

South America

174

 

235

 

(26

)%

Australia

269

 

258

 

4

%

Africa

205

 

186

 

10

%

Nevada

303

 

329

 

(8

)%

Total Gold (excluding equity method investments)

1,364

 

1,384

 

(1

)%

Pueblo Viejo (40%) (2)

91

 

95

 

(4

)%

Total Gold

1,455

 

1,479

 

(2

)%

 

 

 

 

North America

285

 

310

 

(8

)%

Australia

32

 

29

 

10

%

Total Gold Equivalent Ounces

317

 

339

 

(6

)%

 

 

 

 

CAS Consolidated ($/oz, $/GEO)

 

 

 

North America

$

736

 

$

863

 

(15

)%

South America

$

791

 

$

806

 

(2

)%

Australia

$

750

 

$

730

 

3

%

Africa

$

758

 

$

737

 

3

%

Nevada

$

745

 

$

733

 

2

%

Total Gold

$

752

 

$

781

 

(4

)%

Total Gold (by-product)

$

605

 

$

734

 

(18

)%

 

 

 

 

North America

$

518

 

$

580

 

(11

)%

Australia

$

935

 

$

813

 

15

%

Total Gold Equivalent Ounces

$

555

 

$

602

 

(8

)%

 

 

 

 

AISC Consolidated ($/oz, $/GEO)

 

 

 

North America

$

957

 

$

1,067

 

(10

)%

South America

$

1,063

 

$

997

 

7

%

Australia

$

1,104

 

$

949

 

16

%

Africa

$

950

 

$

930

 

2

%

Nevada

$

868

 

$

927

 

(6

)%

Total Gold

$

1,039

 

$

1,030

 

1

%

Total Gold (by-product)

$

953

 

$

1,040

 

(8

)%

 

 

 

 

North America

$

763

 

$

841

 

(9

)%

Australia

$

1,404

 

$

1,035

 

36

%

Total Gold Equivalent Ounces

$

819

 

$

860

 

(5

)%

(1)

Attributable gold ounces from the Pueblo Viejo mine, an equity method investment, are not included in attributable gold ounces sold.

(2)

Represents attributable gold from Pueblo Viejo and does not include the Company’s other equity method investments. Attributable gold ounces produced at Pueblo Viejo are

not included in attributable gold ounces sold, as noted in footnote 1. Income and expenses of equity method investments are included in Equity income (loss) of affiliates.

 

NEWMONT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in millions except per share)

 

 

 

Three Months Ended March 31,

 

2021

 

 

2020

 

 

 

 

 

Sales

$

2,872

 

 

 

$

2,581

 

 

 

 

 

 

Costs and expenses

 

 

 

Costs applicable to sales (1)

1,247

 

 

 

1,332

 

 

Depreciation and amortization

553

 

 

 

565

 

 

Reclamation and remediation

46

 

 

 

38

 

 

Exploration

35

 

 

 

44

 

 

Advanced projects, research and development

31

 

 

 

27

 

 

General and administrative

65

 

 

 

65

 

 

Other expense, net

39

 

 

 

53

 

 

 

2,016

 

 

 

2,124

 

 

Other income (expense):

 

 

 

Gain on asset and investment sales, net

43

 

 

 

593

 

 

Other income, net

(82

)

 

 

(189

)

 

Interest expense, net of capitalized interest

(74

)

 

 

(82

)

 

 

(113

)

 

 

322

 

 

Income (loss) before income and mining tax and other items

743

 

 

 

779

 

 

Income and mining tax benefit (expense)

(235

)

 

 

23

 

 

Equity income (loss) of affiliates

50

 

 

 

37

 

 

Net income (loss) from continuing operations

558

 

 

 

839

 

 

Net income (loss) from discontinued operations

21

 

 

 

(15

)

 

Net income (loss)

579

 

 

 

824

 

 

Net loss (income) attributable to noncontrolling interests

(20

)

 

 

(2

)

 

Net income (loss) attributable to Newmont stockholders

$

559

 

 

 

$

822

 

 

 

 

 

 

Net income (loss) attributable to Newmont stockholders:

 

 

 

Continuing operations

$

538

 

 

 

$

837

 

 

Discontinued operations

21

 

 

 

(15

)

 

 

$

559

 

 

 

$

822

 

 

Net income (loss) per common share

 

 

 

Basic:

 

 

 

Continuing operations

$

0.67

 

 

 

$

1.04

 

 

Discontinued operations

0.03

 

 

 

(0.02

)

 

 

$

0.70

 

 

 

$

1.02

 

 

Diluted:

 

 

 

Continuing operations

$

0.67

 

 

 

$

1.04

 

 

Discontinued operations

0.03

 

 

 

(0.02

)

 

 

$

0.70

 

 

 

$

1.02

 

 

(1)

Excludes Depreciation andamortization and Reclamation and remediation.

NEWMONT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in millions)

 

 

 

Three Months Ended March 31,

 

2021

 

 

2020

 

Operating activities:

 

 

 

Net income (loss)

$

579

 

 

 

$

824

 

 

Adjustments:

 

 

 

Depreciation and amortization

553

 

 

 

565

 

 

Gain on asset and investment sales, net

(43

)

 

 

(593

)

 

Net loss (income) from discontinued operations

(21

)

 

 

15

 

 

Change in fair value of investments

110

 

 

 

93

 

 

Reclamation and remediation

43

 

 

 

35

 

 

Deferred income taxes

(25

)

 

 

(118

)

 

Stock-based compensation

17

 

 

 

21

 

 

Impairment of investments

 

 

 

93

 

 

Charges from debt extinguishment

 

 

 

74

 

 

Other non-cash adjustments

(47

)

 

 

(97

)

 

Net change in operating assets and liabilities

(325

)

 

 

27

 

 

Net cash provided by (used in) operating activities of continuing operations

841

 

 

 

939

 

 

Net cash provided by (used in) operating activities of discontinued operations

 

 

 

(3

)

 

Net cash provided by (used in) operating activities

841

 

 

 

936

 

 

 

 

 

 

Investing activities:

 

Additions to property, plant and mine development

(399

)

 

 

(328

)

 

Proceeds from sales of investments

62

 

 

 

264

 

 

Contributions to equity method investees

(27

)

 

 

(5

)

 

Return of investment from equity method investees

18

 

 

 

43

 

 

Purchases of investments

(4

)

 

 

(12

)

 

Proceeds from sales of mining operations and other assets, net

1

 

 

 

1,121

 

 

Other

(1

)

 

 

40

 

 

Net cash provided by (used in) investing activities

(350

)

 

 

1,123

 

 

 

 

 

 

Financing activities:

 

Dividends paid to common stockholders

(441

)

 

 

(112

)

 

Distributions to noncontrolling interests

(54

)

 

 

(46

)

 

Funding from noncontrolling interests

30

 

 

 

28

 

 

Payments for withholding of employee taxes related to stock-based compensation

(28

)

 

 

(36

)

 

Payments on lease and other financing obligations

(18

)

 

 

(16

)

 

Repayment of debt

 

 

 

(1,070

)

 

Proceeds from issuance of debt, net

 

 

 

985

 

 

Repurchases of common stock

 

 

 

(321

)

 

Other

 

 

 

2

 

 

Net cash provided by (used in) financing activities

(511

)

 

 

(586

)

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(2

)

 

 

(4

)

 

Net change in cash, cash equivalents and restricted cash

(22

)

 

 

1,469

 

 

Cash, cash equivalents and restricted cash at beginning of period

5,648

 

 

 

2,349

 

 

Cash, cash equivalents and restricted cash at end of period

$

5,626

 

 

 

$

3,818

 

 

NEWMONT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in millions)

 

 

 

Three Months Ended March 31,

 

2021

 

2020

Reconciliation of cash, cash equivalents and restricted cash:

 

Cash and cash equivalents

$

5,518

 

 

$

3,709

 

Restricted cash included in Other current assets

2

 

 

2

 

Restricted cash included in Other non-current assets

106

 

 

107

 

Total cash, cash equivalents and restricted cash

$

5,626

 

 

$

3,818

 

NEWMONT CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited, in millions)

 

 

At March 31,

2021

 

At December 31,

2020

ASSETS

 

 

 

Cash and cash equivalents

$

5,518

 

 

 

$

5,540

 

 

Trade receivables

263

 

 

 

449

 

 

Investments

240

 

 

 

290

 

 

Inventories

971

 

 

 

963

 

 

Stockpiles and ore on leach pads

890

 

 

 

827

 

 

Other current assets

482

 

 

 

436

 

 

Current assets

8,364

 

 

 

8,505

 

 

Property, plant and mine development, net

24,081

 

 

 

24,281

 

 

Investments

3,165

 

 

 

3,197

 

 

Stockpiles and ore on leach pads

1,746

 

 

 

1,705

 

 

Deferred income tax assets

332

 

 

 

337

 

 

Goodwill

2,771

 

 

 

2,771

 

 

Other non-current assets

604

 

 

 

573

 

 

Total assets

$

41,063

 

 

 

$

41,369

 

 

 

 

 

 

LIABILITIES

 

 

 

Accounts payable

$

446

 

 

 

$

493

 

 

Employee-related benefits

262

 

 

 

380

 

 

Income and mining taxes payable

454

 

 

 

657

 

 

Lease and other financing obligations

109

 

 

 

106

 

 

Debt

1,042

 

 

 

551

 

 

Other current liabilities

1,167

 

 

 

1,182

 

 

Current liabilities

3,480

 

 

 

3,369

 

 

Debt

4,988

 

 

 

5,480

 

 

Lease and other financing obligations

575

 

 

 

565

 

 

Reclamation and remediation liabilities

3,841

 

 

 

3,818

 

 

Deferred income tax liabilities

2,039

 

 

 

2,073

 

 

Employee-related benefits

504

 

 

 

493

 

 

Silver streaming agreement

958

 

 

 

993

 

 

Other non-current liabilities

686

 

 

 

699

 

 

Total liabilities

17,071

 

 

 

17,490

 

 

 

 

 

 

Contingently redeemable noncontrolling interest

34

 

 

 

34

 

 

 

 

 

 

EQUITY

 

 

 

Common stock

1,289

 

 

 

1,287

 

 

Treasury stock

(196

)

 

 

(168

)

 

Additional paid-in capital

18,119

 

 

 

18,103

 

 

Accumulated other comprehensive income (loss)

(205

)

 

 

(216

)

 

Retained earnings

4,120

 

 

 

4,002

 

 

Newmont stockholders’ equity

23,127

 

 

 

23,008

 

 

Noncontrolling interests

831

 

 

 

837

 

 

Total equity

23,958

 

 

 

23,845

 

 

Total liabilities and equity

$

41,063

 

 

 

$

41,369

 

 

Non-GAAP Financial Measures

Non-GAAP financial measures are intended to provide additional information only and do not have any standard meaning prescribed by U.S. generally accepted accounting principles (“GAAP”). These measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. Unless otherwise noted, we present the Non-GAAP financial measures of our continuing operations in the tables below.

Adjusted net income (loss)

Management uses Adjusted net income (loss) to evaluate the Company’s operating performance and for planning and forecasting future business operations. The Company believes the use of Adjusted net income (loss) allows investors and analysts to understand the results of the continuing operations of the Company and its direct and indirect subsidiaries relating to the sale of products, by excluding certain items that have a disproportionate impact on our results for a particular period. Adjustments to continuing operations are presented before tax and net of our partners’ noncontrolling interests, when applicable. The tax effect of adjustments is presented in the Tax effect of adjustments line and is calculated using the applicable regional tax rate. Management’s determination of the components of Adjusted net income (loss) are evaluated periodically and based, in part, on a review of non-GAAP financial measures used by mining industry analysts. Net income (loss) attributable to Newmont stockholders is reconciled to Adjusted net income (loss) as follows:

 

Three Months Ended

March 31, 2021

 

 

 

per share data (1)

 

 

 

basic

 

diluted

Net income (loss) attributable to Newmont stockholders

$

559

 

 

 

$

0.70

 

 

 

$

0.70

 

 

Net loss (income) attributable to Newmont stockholders from discontinued operations

(21

)

 

 

(0.03

)

 

 

(0.03

)

 

Net income (loss) attributable to Newmont stockholders from continuing operations

538

 

 

 

0.67

 

 

 

0.67

 

 

Change in fair value of investments (2)

110

 

 

 

0.14

 

 

 

0.14

 

 

(Gain) loss on asset and investment sales (3)

(43

)

 

 

(0.05

)

 

 

(0.05

)

 

Reclamation and remediation charges (4)

10

 

 

 

0.01

 

 

 

0.01

 

 

Restructuring and severance, net (5)

4

 

 

 

 

 

 

 

 

Settlement costs (6)

3

 

 

 

 

 

 

 

 

COVID-19 specific costs (7)

1

 

 

 

 

 

 

 

 

Impairment of long-lived and other assets (8)

1

 

 

 

 

 

 

 

 

Tax effect of adjustments (9)

(19

)

 

 

(0.02

)

 

 

(0.02

)

 

Valuation allowance and other tax adjustments, net (10)

(11

)

 

 

(0.01

)

 

 

(0.01

)

 

Adjusted net income (loss)

$

594

 

 

 

$

0.74

 

 

 

$

0.74

 

 

 

 

 

 

 

Weighted average common shares (millions): (11)

 

 

801

 

 

 

802

 

 

(1)

Per share measures may not recalculate due to rounding.

(2)

Change in fair value of investments, included in Other income, net, primarily represents unrealized holding gains and losses on marketable equity securities and our investment instruments.

(3)

(Gain) loss on asset and investment sales, included in Gain on asset and investment sales, net, primarily represents a gain on the sale of TMAC.

(4)

Reclamation and remediation charges, included in Reclamation and remediation, represent revisions to reclamation and remediation plans at the Company’s former operating properties and historic mining operations that have entered the closure phase and have no substantive future economic value.

(5)

Restructuring and severance, net, included in Other expense, net, primarily represents severance and related costs associated with significant organizational or operating model changes implemented by the Company. Total amount is presented net of income (loss) attributable to noncontrolling interests of $(1).

(6)

Settlement costs, included in Other expense, net, primarily represents certain costs associated with legal and other settlements.

(7)

COVID-19 specific costs, included in Other expense, net, primarily includes amounts distributed from the Newmont Global Community Support Fund to help host communities, governments and employees combat the COVID-19 pandemic. Adjusted net income (loss) has not been adjusted for $21 of incremental COVID-19 costs incurred as a result of actions taken to protect against the impacts of the COVID-19 pandemic at our operational sites.

(8)

Impairment of long-lived and other assets, included in Other expense, net, represents non-cash write-downs of various assets that are no longer in use.

(9)

The tax effect of adjustments, included in Income and mining tax benefit (expense), represents the tax effect of adjustments in footnotes (2) through (8), as described above, and are calculated using the applicable regional tax rate.

(10)

Valuation allowance and other tax adjustments, net, included in Income and mining tax benefit (expense), is recorded for items such as foreign tax credits, alternative minimum tax credits, capital losses, disallowed foreign losses, and the effects of changes in foreign currency exchange rates on deferred tax assets and deferred tax liabilities. The adjustment is due to a net increase or (decrease) to capital losses, tax credit carryovers and other deferred tax assets subject to valuation allowance of $21, the effects of changes in foreign exchange rates on deferred tax assets and liabilities of $(28), and other tax adjustments of $(2). Total amount is presented net of income (loss) attributable to noncontrolling interests of $(2).

(11)

Adjusted net income (loss) per diluted share is calculated using diluted common shares, which are calculated in accordance with U.S. GAAP.

 

Three Months Ended

March 31, 2020

 

 

 

per share data (1)

 

 

 

basic

 

diluted

Net income (loss) attributable to Newmont stockholders

$

822

 

 

 

$

1.02

 

 

 

$

1.02

 

 

Net loss (income) attributable to Newmont stockholders from discontinued operations

15

 

 

 

0.02

 

 

 

0.02

 

 

Net income (loss) attributable to Newmont stockholders from continuing operations

837

 

 

 

1.04

 

 

 

1.04

 

 

(Gain) loss on asset and investment sales (2)

(593

)

 

 

(0.73

)

 

 

(0.73

)

 

Change in fair value of investments (3)

93

 

 

 

0.11

 

 

 

0.11

 

 

Impairment of investments (4)

93

 

 

 

0.11

 

 

 

0.11

 

 

Loss on debt extinguishment (5)

74

 

 

 

0.09

 

 

 

0.09

 

 

Goldcorp transaction and integration costs (6)

16

 

 

 

0.02

 

 

 

0.02

 

 

Settlement costs (7)

6

 

 

 

 

 

 

 

 

COVID-19 specific costs (8)

2

 

 

 

 

 

 

 

 

Restructuring and severance (9)

1

 

 

 

 

 

 

 

 

Tax effect of adjustments (10)

93

 

 

 

0.13

 

 

 

0.13

 

 

Valuation allowance and other tax adjustments, net (11)

(296

)

 

 

(0.37

)

 

 

(0.37

)

 

Adjusted net income (loss) (12)

$

326

 

 

 

$

0.40

 

 

 

$

0.40

 

 

 

 

 

 

 

 

Weighted average common shares (millions): (13)

 

 

807

 

 

 

809

 

 

(1)

Per share measures may not recalculate due to rounding.

(2)

(Gain) loss on asset and investment sales, included in Gain on asset and investment sales, net, primarily represents gains on the sale of Kalgoorlie and Continental.

(3)

Change in fair value of investments, included in Other income, net, primarily represents unrealized holding gains and losses on marketable equity securities and our investment instruments.

(4)

Impairment of investments, included in Other income, net, represents the other-than-temporary impairment of the TMAC investment.

(5)

Loss on debt extinguishment, included in Other income, net, primarily represents losses on the extinguishment of a portion of the 2022 Senior Notes and 2023 Senior Notes.

(6)

Goldcorp transaction and integration costs, included in Other expense, net, primarily represents incremental direct costs incurred related to the Newmont Goldcorp transaction.

(7)

Settlement costs, included in Other expense, net, primarily represents certain costs associated with legal and other settlements.

(8)

COVID-19 specific costs, included in Other expense, net, represents incremental direct costs incurred as a result of actions taken to protect against the impacts of the COVID-19 pandemic.

(9)

Restructuring and severance, included in Other expense, net, primarily represents certain costs associated with severance and legal costs.

(10)

The tax effect of adjustments, included in Income and mining tax benefit (expense), represents the tax effect of adjustments in footnotes (2) through (9), as described above, and are calculated using the applicable regional tax rate.

(11)

Valuation allowance and other tax adjustments, included in Income and mining tax benefit (expense), is recorded for items such as foreign tax credits, alternative minimum tax credits, capital losses, disallowed foreign losses, and the effects of changes in foreign currency exchange rates on deferred tax assets and deferred tax liabilities. The adjustment is due to a net increase or (decrease) to net operating losses, tax credit carryovers and other deferred tax assets subject to valuation allowance of $(109), the effects of changes in foreign exchange rates on deferred tax assets and liabilities of $(179), reductions to the reserve for uncertain tax positions of $(24) and other tax adjustments of $31. Amounts are presented net of income (loss) attributable to noncontrolling interests of $(15).

(12)

Adjusted net income (loss) has not been adjusted for $18 of cash and $6 of non-cash care and maintenance costs, included in Other expense, net and Depreciation and amortization, respectively, which primarily represent costs associated with our Musselwhite, Éléonore, Yanacocha and Cerro Negro mine sites being temporarily placed into care and maintenance in response to the COVID-19 pandemic during the period ended March 31, 2020. Amounts are presented net of income (loss) attributable to noncontrolling interests of $2 and $1, respectively.

(13)

Adjusted net income (loss) per diluted share is calculated using diluted common shares, which are calculated in accordance with U.S. GAAP.

Earnings before interest, taxes and depreciation and amortization and Adjusted earnings before interest, taxes and depreciation and amortization

Management uses Earnings before interest, taxes and depreciation and amortization (“EBITDA”) and EBITDA adjusted for non-core or certain items that have a disproportionate impact on our results for a particular period (“Adjusted EBITDA”) as non-GAAP measures to evaluate the Company’s operating performance. EBITDA and Adjusted EBITDA do not represent, and should not be considered an alternative to, net income (loss), operating income (loss), or cash flow from operations as those terms are defined by GAAP, and do not necessarily indicate whether cash flows will be sufficient to fund cash needs. Although Adjusted EBITDA and similar measures are frequently used as measures of operations and the ability to meet debt service requirements by other companies, our calculation of Adjusted EBITDA is not necessarily comparable to such other similarly titled captions of other companies. The Company believes that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Management’s determination of the components of Adjusted EBITDA are evaluated periodically and based, in part, on a review of non-GAAP financial measures used by mining industry analysts. Net income (loss) attributable to Newmont stockholders is reconciled to EBITDA and Adjusted EBITDA as follows:

Three Months Ended March 31,

2021

 

 

2020

 

Net income (loss) attributable to Newmont stockholders

$

559

 

 

 

$

822

 

 

Net income (loss) attributable to noncontrolling interests

20

 

 

 

2

 

 

Net loss (Income) from discontinued operations

(21

)

 

 

15

 

 

Equity loss (income) of affiliates

(50

)

 

 

(37

)

 

Income and mining tax expense (benefit)

235

 

 

 

(23

)

 

Depreciation and amortization

553

 

 

 

565

 

 

Interest expense, net

74

 

 

 

82

 

 

EBITDA

$

1,370

 

 

 

$

1,426

 

 

Adjustments:

 

 

 

Change in fair value of investments (1)

$

110

 

 

 

$

93

 

 

(Gain) loss on asset and investment sales (2)

(43

)

 

 

(593

)

 

Reclamation and remediation charges (3)

10

 

 

 

 

 

Restructuring and severance (4)

5

 

 

 

1

 

 

Settlement costs (5)

3

 

 

 

6

 

 

COVID-19 specific costs (6)

1

 

 

 

2

 

 

Impairment of long-lived and other assets (7)

1

 

 

 

 

 

Impairment of investments (8)

 

 

 

93

 

 

Loss on debt extinguishment (9)

 

 

 

74

 

 

Goldcorp transaction and integration costs (10)

 

 

 

16

 

 

Adjusted EBITDA (11)

$

1,457

 

 

 

$

1,118

 

 

(1)

Change in fair value of investments, included in Other income, net, primarily represents unrealized holding gains and losses on marketable equity securities and our investment instruments.

(2)

(Gain) loss on asset and investment sales, included in Gain on asset and investment sales, net, primarily represents a gain on the sale of TMAC in 2021 and gains on the sale of Kalgoorlie and Continental in 2020.

(3)

Reclamation and remediation charges, included in Reclamation and remediation, represent revisions to reclamation and remediation plans at the Company’s former operating properties and historic mining operations that have entered the closure phase and have no substantive future economic value.

(4)

Restructuring and severance, included in Other expense, net, primarily represents severance and related costs associated with significant organizational or operating model changes implemented by the Company for all periods presented.

(5)

Settlement costs, included in Other expense, net, primarily represents certain costs associated with legal and other settlements.

(6)

COVID-19 specific costs, included in Other expense, net, primarily includes amounts distributed from the Newmont Global Community Support Fund to help host communities, governments and employees combat the COVID-19 pandemic. For the period ended March 31, 2021, Adjusted EBITDA has not been adjusted for $21 of incremental COVID-19 costs incurred as a result of actions taken to protect against the impacts of the COVID-19 pandemic at our operational sites.

(7)

Impairment of long-lived and other assets, included in Other expense, net, represents non-cash write-downs of various assets that are no longer in use.

(8)

Impairment of investments, included in Other income, net, primarily represents the other-than-temporary impairment of the TMAC investment recorded in 2020.

(9)

Loss on debt extinguishment, included in Other income, net, primarily represents losses on the extinguishment of a portion of the 2022 Senior Notes and 2023 Senior Notes during 2020.

(10)

Goldcorp transaction and integration costs, included in Other expense, net, primarily represents subsequent integration costs incurred during 2020 related to the Newmont Goldcorp transaction.

(11)

Adjusted EBITDA has not been adjusted for $— and $20 during the periods ended March 31, 2021 and March 31, 2020, respectively, of cash care and maintenance costs, included in Other expense, net, which primarily represent costs incurred associated with our Musselwhite, Éléonore, Yanacocha and Cerro Negro mine sites being temporarily placed into care and maintenance in response to the COVID-19 pandemic.

Additionally, the Company uses Pueblo Viejo EBITDA as a non-GAAP measure to evaluate the operating performance of its investment in the Pueblo Viejo mine. Pueblo Viejo EBITDA does not represent, and should not be considered an alternative to, Equity income (loss) of affiliates, as defined by GAAP, and does not necessarily indicate whether cash distributions from Pueblo Viejo will match Pueblo Viejo EBITDA or earnings from affiliates. Although the Company has the ability to exert significant influence, it does not have direct control over the operations or resulting revenues and expenses, nor does it proportionately consolidate its investment in Pueblo Viejo. The Company believes that Pueblo Viejo EBITDA provides useful information to investors and others in understanding and evaluating the operating results of its investment in Pueblo Viejo, in the same manner as management and the Board of Directors. Equity income (loss) of affiliates is reconciled to Pueblo Viejo EBITDA as follows:​

 

Three Months Ended March 31,

 

2021

 

2020

 

 

 

 

Equity income (loss) of affiliates

$

50

 

 

$

37

 

Equity (income) loss of affiliates, excluding Pueblo Viejo (1)

 

 

11

 

Equity income (loss) of affiliates, Pueblo Viejo (1)

50

 

 

48

 

Reconciliation of Pueblo Viejo on attributable basis:

 

 

 

Income and mining tax expense (benefit), Pueblo Viejo

47

 

 

37

 

Depreciation and amortization, Pueblo Viejo

20

 

 

16

 

Pueblo Viejo EBITDA

$

117

 

 

$

101

 

(1)

See Note 10 to the Condensed Consolidated Financial Statements.

The Company uses NGM EBITDA as a non-GAAP measure to evaluate the operating performance of its investment in Nevada Gold Mines (NGM). NGM EBITDA does not represent, and should not be considered an alternative to, Income (loss) before income and mining tax and other items, as defined by GAAP, and does not necessarily indicate whether cash distributions from NGM will match NGM EBITDA. Although the Company has the ability to exert significant influence and proportionally consolidates its 38.5% interest in NGM, it does not have direct control over the operations or resulting revenues and expenses of its investment in NGM. The Company believes that NGM EBITDA provides useful information to investors and others in understanding and evaluating the operating results of its investment in NGM, in the same manner as management and the Board of Directors. Income (loss) before income and mining tax and other items is reconciled to NGM EBITDA as follows:

 

Three Months Ended March 31,

 

2021

 

2020

Income (Loss) before Income and Mining Tax and other Items, NGM (1)

$

167

 

 

$

133

 

Depreciation and amortization, NGM (1)

127

 

 

131

 

NGM EBITDA

$

294

 

 

$

264

 

(1)

See Note 3 to the Condensed Consolidated Financial Statements.

Free Cash Flow

Management uses Free Cash Flow as a non-GAAP measure to analyze cash flows generated from operations. Free Cash Flow is Net cash provided by (used in) operating activities less Net cash provided by (used in) operating activities of discontinued operations less Additions to property, plant and mine development as presented on the Condensed Consolidated Statements of Cash Flows. The Company believes Free Cash Flow is also useful as one of the bases for comparing the Company’s performance with its competitors. Although Free Cash Flow and similar measures are frequently used as measures of cash flows generated from operations by other companies, the Company’s calculation of Free Cash Flow is not necessarily comparable to such other similarly titled captions of other companies.

The presentation of non-GAAP Free Cash Flow is not meant to be considered in isolation or as an alternative to net income as an indicator of the Company’s performance, or as an alternative to cash flows from operating activities as a measure of liquidity as those terms are defined by GAAP, and does not necessarily indicate whether cash flows will be sufficient to fund cash needs. The Company’s definition of Free Cash Flow is limited in that it does not represent residual cash flows available for discretionary expenditures due to the fact that the measure does not deduct the payments required for debt service and other contractual obligations or payments made for business acquisitions. Therefore, the Company believes it is important to view Free Cash Flow as a measure that provides supplemental information to the Company’s Condensed Consolidated Statements of Cash Flows.

The following table sets forth a reconciliation of Free Cash Flow, a non-GAAP financial measure, to Net cash provided by (used in) operating activities, which the Company believes to be the GAAP financial measure most directly comparable to Free Cash Flow, as well as information regarding Net cash provided by (used in) investing activities and Net cash provided by (used in) financing activities.

 

Three Months Ended

March 31,

 

2021

 

 

2020

 

Net cash provided by (used in) operating activities

$

841

 

 

 

$

936

 

 

Less: Net cash used in (provided by) operating activities of discontinued operations

 

 

 

3

 

 

Net cash provided by (used in) operating activities of continuing operations

841

 

 

 

939

 

 

Less: Additions to property, plant and mine development

(399

)

 

 

(328

)

 

Free Cash Flow

$

442

 

 

 

$

611

 

 

 

 

 

 

Net cash provided by (used in) investing activities (1)

$

(350

)

 

 

$

1,123

 

 

Net cash provided by (used in) financing activities

$

(511

)

 

 

$

(586

)

 

(1)

Net cash provided by (used in) investing activities includes Additions to property plant and mine development, which is included in the Company’s computation of Free Cash Flow.​

Attributable Free Cash Flow

Management uses Attributable Free Cash Flow as a non-GAAP measure to analyze cash flows generated from operations that are attributable to the Company. Attributable Free Cash Flow is Net cash provided by (used in) operating activities after deducting net cash flows from operations attributable to noncontrolling interests less Net cash provided by (used in) operating activities of discontinued operations after deducting net cash flows from discontinued operations attributable to noncontrolling interests less Additions to property, plant and mine development after deducting property, plant and mine development attributable to noncontrolling interests. The Company believes that Attributable Free Cash Flow is useful as one of the bases for comparing the Company’s performance with its competitors. Although Attributable Free Cash Flow and similar measures are frequently used as measures of cash flows generated from operations by other companies, the Company’s calculation of Attributable Free Cash Flow is not necessarily comparable to such other similarly titled captions of other companies.

The presentation of non-GAAP Attributable Free Cash Flow is not meant to be considered in isolation or as an alternative to Net income attributable to Newmont stockholders as an indicator of the Company’s performance, or as an alternative to Net cash provided by (used in) operating activities as a measure of liquidity as those terms are defined by GAAP, and does not necessarily indicate whether cash flows will be sufficient to fund cash needs. The Company’s definition of Attributable Free Cash Flow is limited in that it does not represent residual cash flows available for discretionary expenditures due to the fact that the

measure does not deduct the payments required for debt service and other contractual obligations or payments made for business acquisitions. Therefore, the Company believes it is important to view Attributable Free Cash Flow as a measure that provides supplemental information to the Company’s Condensed Consolidated Statements of Cash Flows.

The following tables set forth a reconciliation of Attributable Free Cash Flow, a non-GAAP financial measure, to Net cash provided by (used in) operating activities, which the Company believes to be the GAAP financial measure most directly comparable to Attributable Free Cash Flow, as well as information regarding Net cash provided by (used in) investing activities and Net cash provided by (used in) financing activities.

 

Three Months Ended March 31, 2021

 

Three Months Ended March 31, 2020

 

Consolidated

 

Attributable to noncontrolling interests (1)

 

Attributable to Newmont Stockholders

 

Consolidated

 

Attributable to noncontrolling interests (1)

 

Attributable to Newmont Stockholders

Net cash provided by (used in) operating activities

$

841

 

 

 

$

(20

)

 

 

$

821

 

 

 

$

936

 

 

 

$

(53

)

 

 

$

883

 

 

Less: Net cash used in (provided by) operating activities of discontinued operations

 

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

3

 

 

Net cash provided by (used in) operating activities of continuing operations

841

 

 

 

(20

)

 

 

821

 

 

 

939

 

 

 

(53

)

 

 

886

 

 

Less: Additions to property, plant and mine development (2)

(399

)

 

 

16

 

 

 

(383

)

 

 

(328

)

 

 

12

 

 

 

(316

)

 

Free Cash Flow

$

442

 

 

 

$

(4

)

 

 

$

438

 

 

 

$

611

 

 

 

$

(41

)

 

 

$

570

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) investing activities (3)

$

(350

)

 

 

 

 

 

 

$

1,123

 

 

 

 

 

 

Net cash provided by (used in) financing activities

$

(511

)

 

 

 

 

 

 

$

(586

)

 

 

 

 

 

(1)

Adjustment to eliminate a portion of Net cash provided by (used in) operating activities,Net cash provided by (used in) operating activities of discontinued operations and Additions to property,plant and mine development attributable to noncontrolling interests, which relate to Yanacocha (48.65%) and Merian (25%).

(2)

For the three months ended March 31, 2021, Yanacocha and Merian had total consolidated Additions to property,plant and mine development of $28 and $11, respectively, on a cash basis. For the three months ended March 31, 2020, Yanacocha and Merian had total consolidated Additions to property,plant and mine development of $21 and $9, respectively, on a cash basis.

(3)

Net cash provided by (used in) investing activities includes Additions to property,plant and mine development, which is included in the Company’s computation of Free Cash Flow.​

Costs applicable to sales per ounce/gold equivalent ounce

Costs applicable to sales per ounce/gold equivalent ounce are non-GAAP financial measures. These measures are calculated by dividing the costs applicable to sales of gold and other metals by gold ounces or gold equivalent ounces sold, respectively. These measures are calculated for the periods presented on a consolidated basis. Costs applicable to sales per ounce/gold equivalent ounce statistics are intended to provide additional information only and do not have any standardized meaning prescribed by GAAP and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The measures are not necessarily indicative of operating profit or cash flow from operations as determined under GAAP. Other companies may calculate these measures differently.

The following tables reconcile these non-GAAP measures to the most directly comparable GAAP measures.

Costs applicable to sales per ounce

 

Three Months Ended

March 31,

 

2021

 

2020

Costs applicable to sales (1)(2)

$

1,065

 

 

$

1,140

 

Gold sold (thousand ounces)

1,417

 

 

1,460

 

Costs applicable to sales per ounce (3)

$

752

 

 

$

781

 

(1)

Includes by-product credits of $55 and $24 during the three months ended March 31, 2021 and 2020, respectively.

(2)

Excludes Depreciation and amortization and Reclamation and remediation.

(3)

Per ounce measures may not recalculate due to rounding.

Costs applicable to sales per gold equivalent ounce

 

Three Months Ended

March 31,

 

2021

 

2020

Costs applicable to sales (1)(2)

$

182

 

 

$

192

 

Gold equivalent ounces – other metals (thousand ounces) (3)

327

 

 

319

 

Costs applicable to sales per ounce (4)

$

555

 

 

$

602

 

(1)

Includes by-product credits of $1 and $— during the three months ended March 31, 2021 and 2020, respectively.

(2)

Excludes Depreciation and amortization and Reclamation and remediation.

(3)

Gold equivalent ounces is calculated as pounds or ounces produced multiplied by the ratio of the other metals price to the gold price, using Gold ($1,200/oz.), Copper ($2.75/lb.), Silver ($22.00/oz.), Lead ($0.90/lb.) and Zinc ($1.05/lb.) pricing for 2021 and Gold ($1,200/oz.), Copper ($2.75/lb.), Silver ($16.00/oz.), Lead ($0.95/lb.) and Zinc ($1.20/lb.) pricing for 2020.

(4)

Per ounce measures may not recalculate due to rounding.​

Costs applicable to sales per ounce for Nevada Gold Mines (NGM)

 

Three Months Ended

March 31,

 

2021

 

2020

Cost applicable to sales, NGM (1)(2)

$

227

 

 

$

243

 

Gold sold (thousand ounces), NGM

305

 

 

332

 

Costs applicable to sales per ounce, NGM (3)

$

745

 

 

$

733

 

(1)

See Note 3 to the Condensed Consolidated Financial Statements

(2)

Excludes Depreciation and amortization and Reclamation and remediation.

(3)

Per ounce measures may not recalculate due to rounding.

All-In Sustaining Costs

Newmont has developed a metric that expands on GAAP measures, such as cost of goods sold, and non-GAAP measures, such as costs applicable to sales per ounce, to provide visibility into the economics of our mining operations related to expenditures, operating performance and the ability to generate cash flow from our continuing operations.

Current GAAP measures used in the mining industry, such as cost of goods sold, do not capture all of the expenditures incurred to discover, develop and sustain production. Therefore, we believe that all-in sustaining costs is a non-GAAP measure that provides additional information to management, investors and analysts that aid in the understanding of the economics of our operations and performance compared to other producers and provides investors visibility by better defining the total costs associated with production.

All-in sustaining cost (“AISC”) amounts are intended to provide additional information only and do not have any standardized meaning prescribed by GAAP and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The measures are not necessarily indicative of operating profit or cash flow from operations as determined under GAAP. Other companies may calculate these measures differently as a result of differences in the underlying accounting principles, policies applied and in accounting frameworks such as in International Financial Reporting Standards (“IFRS”), or by reflecting the benefit from selling non-gold metals as a reduction to AISC. Differences may also arise related to definitional differences of sustaining versus development (i.e. non-sustaining) activities based upon each company’s internal policies.

The following disclosure provides information regarding the adjustments made in determining the All-in sustaining costs measure:

Costs applicable to sales. Includes all direct and indirect costs related to current production incurred to execute the current mine plan. We exclude certain exceptional or unusual amounts from Costs applicable to sales (“CAS”), such as significant revisions to recovery amounts. CAS includes by-product credits from certain metals obtained during the process of extracting and processing the primary ore-body. CAS is accounted for on an accrual basis and excludes Depreciation and amortization and Reclamation and remediation, which is consistent with our presentation of CAS on the Condensed Consolidated Statements of Operations. In determining AISC, only the CAS associated with producing and selling an ounce of gold is included in the measure. Therefore, the amount of gold CAS included in AISC is derived from the CAS presented in the Company’s Condensed Consolidated Statements of Operations less the amount of CAS attributable to the production of other metals at our Peñasquito and Boddington mines. The other metals CAS at those mine sites is disclosed in Note 3 to the Condensed Consolidated Financial Statements. The allocation of CAS between gold and other metals at the Peñasquito and Boddington mines is based upon the relative sales value of gold and other metals produced during the period.

Reclamation costs. Includes accretion expense related to reclamation liabilities and the amortization of the related Asset Retirement Cost (“ARC”) for the Company’s operating properties. Accretion related to the reclamation liabilities and the amortization of the ARC assets for reclamation does not reflect annual cash outflows but are calculated in accordance with GAAP. The accretion and amortization reflect the periodic costs of reclamation associated with current production and are therefore included in the measure. The allocation of these costs to gold and other metals is determined using the same allocation used in the allocation of CAS between gold and other metals at the Peñasquito and Boddington mines.

Advanced projects, research and development and exploration. Includes incurred expenses related to projects that are designed to sustain current production and exploration. We note that as current resources are depleted, exploration and advanced projects are necessary for us to replace the depleting reserves or enhance the recovery and processing of the current reserves to sustain production at existing operations. As these costs relate to sustaining our production, and are considered a continuing cost of a mining company, these costs are included in the AISC measure. These costs are derived from the Advanced projects, research and development and Exploration amounts presented in the Condensed Consolidated Statements of Operations less incurred expenses related to the development of new operations, or related to major projects at existing operations where these projects will materially benefit the operation in the future. The allocation of these costs to gold and other metals is determined using the same allocation used in the allocation of CAS between gold and other metals at the Peñasquito and Boddington mines.

General and administrative. Includes costs related to administrative tasks not directly related to current production, but rather related to support our corporate structure and fulfill our obligations to operate as a public company. Including these expenses in the AISC metric provides visibility of the impact that general and administrative activities have on current operations and profitability on a per ounce basis.

Other expense, net. We exclude certain exceptional or unusual expenses, such as restructuring, as these are not indicative to sustaining our current operations. Furthermore, this adjustment to Other expense, net is also consistent with the nature of the adjustments made to Net income (loss) attributable to Newmont stockholders as disclosed in the Company’s non-GAAP financial measure Adjusted net income (loss). The allocation of these costs to gold and other metals is determined using the same allocation used in the allocation of CAS between gold and other metals at the Peñasquito and Boddington mines.

Treatment and refining costs. Includes costs paid to smelters for treatment and refining of our concentrates to produce the salable metal. These costs are presented net as a reduction of Sales on our Condensed Consolidated Statements of Operations. The allocation of these costs to gold and other metals is determined using the same allocation used in the allocation of CAS between gold and other metals at the Peñasquito and Boddington mines.

Sustaining capital and finance lease payments. We determined sustaining capital and finance lease payments as those capital expenditures and finance lease payments that are necessary to maintain current production and execute the current mine plan. We determined development (i.e. non-sustaining) capital expenditures and finance lease payments to be those payments used to develop new operations or related to projects at existing operations where those projects will materially benefit the operation and are excluded from the calculation of AISC. The classification of sustaining and development capital projects and finance leases is based on a systematic review of our project portfolio in light of the nature of each project. Sustaining capital and finance lease payments are relevant to the AISC metric as these are needed to maintain the Company’s current operations and provide improved transparency related to our ability to finance these expenditures from current operations. The allocation of these costs to gold and other metals is determined using the same allocation used in the allocation of CAS between gold and other metals at the Peñasquito and Boddington mines.

Three Months Ended

March 31, 2021

Costs Applicable to Sales(1)(2)(3)

 

Reclamation Costs(4)

 

Advanced Projects, Research and Development and Exploration(5)

 

General and Administrative

 

Other Expense, Net(6)(7)

 

Treatment and Refining Costs

 

Sustaining Capital and Lease Related Costs(8)(9)

 

All-In Sustaining Costs

 

Ounces (000) Sold

 

All-In Sustaining Costs Per oz.(10)

Gold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CC&V

$

61

 

 

$

2

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

9

 

 

$

72

 

 

56

 

 

$

1,286

 

Musselwhite

39

 

 

 

 

2

 

 

 

 

 

 

 

 

9

 

 

50

 

 

39

 

 

1,305

 

Porcupine

66

 

 

1

 

 

4

 

 

 

 

 

 

 

 

9

 

 

80

 

 

74

 

 

1,104

 

Éléonore

53

 

 

1

 

 

1

 

 

 

 

2

 

 

 

 

18

 

 

75

 

 

61

 

 

1,226

 

Peñasquito

89

 

 

2

 

 

1

 

 

 

 

3

 

 

10

 

 

16

 

 

121

 

 

190

 

 

632

 

Other North America

 

 

 

 

1

 

 

2

 

 

 

 

 

 

 

 

3

 

 

 

 

 

North America

308

 

 

6

 

 

9

 

 

2

 

 

5

 

 

10

 

 

61

 

 

401

 

 

420

 

 

957

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Yanacocha

50

 

 

12

 

 

2

 

 

 

 

8

 

 

 

 

2

 

 

74

 

 

61

 

 

1,215

 

Merian

81

 

 

1

 

 

 

 

 

 

1

 

 

 

 

10

 

 

93

 

 

108

 

 

864

 

Cerro Negro

40

 

 

1

 

 

1

 

 

 

 

6

 

 

 

 

11

 

 

59

 

 

47

 

 

1,263

 

Other South America

 

 

 

 

 

 

2

 

 

1

 

 

 

 

 

 

3

 

 

 

 

 

South America

171

 

 

14

 

 

3

 

 

2

 

 

16

 

 

 

 

23

 

 

229

 

 

216

 

 

1,063

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Boddington

131

 

 

3

 

 

2

 

 

 

 

 

 

3

 

 

56

 

 

195

 

 

146

 

 

1,330

 

Tanami

70

 

 

 

 

1

 

 

 

 

1

 

 

 

 

25

 

 

97

 

 

122

 

 

796

 

Other Australia

 

 

 

 

 

 

3

 

 

 

 

 

 

1

 

 

4

 

 

 

 

 

Australia

201

 

 

3

 

 

3

 

 

3

 

 

1

 

 

3

 

 

82

 

 

296

 

 

268

 

 

1,104

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ahafo

92

 

 

2

 

 

2

 

 

 

 

1

 

 

 

 

17

 

 

114

 

 

104

 

 

1,094

 

Akyem

66

 

 

8

 

 

 

 

 

 

 

 

 

 

8

 

 

82

 

 

104

 

 

788

 

Other Africa

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

2

 

 

 

 

 

Africa

158

 

 

10

 

 

2

 

 

2

 

 

1

 

 

 

 

25

 

 

198

 

 

208

 

 

950

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nevada Gold Mines

227

 

 

2

 

 

2

 

 

3

 

 

 

 

 

 

31

 

 

265

 

 

305

 

 

868

 

Nevada

227

 

 

2

 

 

2

 

 

3

 

 

 

 

 

 

31

 

 

265

 

 

305

 

 

868

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate and Other

 

 

 

 

25

 

 

53

 

 

2

 

 

 

 

3

 

 

83

 

 

 

 

 

Total Gold

$

1,065

 

 

$

35

 

 

$

44

 

 

$

65

 

 

$

25

 

 

$

13

 

 

$

225

 

 

$

1,472

 

 

1,417

 

 

$

1,039

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold equivalent ounces – other metals (11)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Peñasquito

$

155

 

 

$

2

 

 

$

 

 

$

 

 

$

4

 

 

$

43

 

 

$

23

 

 

$

227

 

 

298

 

 

$

763

 

Boddington

27

 

 

1

 

 

 

 

 

 

 

 

1

 

 

12

 

 

41

 

 

29

 

 

1,404

 

Total Gold Equivalent Ounces

$

182

 

 

$

3

 

 

$

 

 

$

 

 

$

4

 

 

$

44

 

 

$

35

 

 

$

268

 

 

327

 

 

$

819

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated

$

1,247

 

 

$

38

 

 

$

44

 

 

$

65

 

 

$

29

 

 

$

57

 

 

$

260

 

 

$

1,740

 

 

 

 

 

(1)

Excludes Depreciation and amortization and Reclamation and remediation.

(2)

Includes by-product credits of $56 and excludes co-product revenues of $390.

(3)

Includes stockpile and leach pad inventory adjustments of $4 at CC&V and $10 at NGM.

(4)

Reclamation costs include operating accretion and amortization of asset retirement costs of $20 and $18, respectively, and exclude accretion and reclamation and remediation adjustments at former operating properties and historic mining operations that have entered the closure phase and have no substantive future economic value of $13 and $13, respectively.

(5)

Advanced projects, research and development and Exploration excludes development expenditures of $2 at CC&V, $1 at Porcupine, $1 at Éléonore, $1 at Yanacocha, $1 at Merian, $6 at Other South America, $2 at Tanami, $2 at Other Australia, $1 at Ahafo, $1 at Akyem and $4 at NGM, totaling $22 related to developing new operations or major projects at existing operations where these projects will materially benefit the operation.

(6)

Other expense, net includes incremental COVID-19 costs incurred as a result of actions taken to protect against the impacts of the COVID-19 pandemic at our operational sites of $7 for North America, $12 for South America, $1 for Australia and $1 for Africa, totaling $21.

(7)

Other expense, net is adjusted for restructuring and severance costs of $5, settlement costs of $3, distributions from the Newmont Global Community Support Fund of $1 and impairment of long-lived and other assets of $1.

(8)

Includes sustaining capital expenditures of $73 for North America, $23 for South America, $88 for Australia, $25 for Africa, $31 for Nevada, and $3 for Corporate and Other, totaling $243 and excludes development capital expenditures, capitalized interest and the change in accrued capital totaling $156. The following are major development projects: Pamour, Yanacocha Sulfides, Quecher Main, Cerro Negro expansion projects, Tanami Expansion 2, Subika Mining Method Change, Ahafo North, Goldrush Complex and Turquoise Ridge 3rd shaft.

(9)

Includes finance lease payments for sustaining projects of $17.

(10)

Per ounce measures may not recalculate due to rounding.

(11)

Gold equivalent ounces is calculated as pounds or ounces produced multiplied by the ratio of the other metals price to the gold price, using Gold ($1,200/oz.), Copper ($2.75/lb.), Silver ($22.00/oz.), Lead ($0.90/lb.) and Zinc ($1.05/lb.) pricing for 2021.

Three Months Ended

March 31, 2020

Costs

Applicable

to

Sales (1)(2)(3)

 

Reclamation

Costs (4)

 

Advanced

Projects,

Research and

Development

and

Exploration(5)

 

General

and

Administrative

 

Other

Expense,

Net (6)(7)

 

Treatment

and

Refining

Costs

 

Sustaining

Capital and Lease Related Costs(8)(9)

 

All-In

Sustaining

Costs

 

Ounces (000)

Sold

 

All-In

Sustaining

Costs per

oz. (10)

Gold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CC&V

$

60

 

 

$

1

 

 

$

1

 

 

$

 

 

$

 

 

$

 

 

$

6

 

 

$

68

 

 

65

 

 

$

1,043

 

Red Lake

45

 

 

 

 

1

 

 

 

 

 

 

 

 

4

 

 

50

 

 

42

 

 

1,182

 

Musselwhite

25

 

 

1

 

 

2

 

 

 

 

3

 

 

 

 

7

 

 

38

 

 

15

 

 

2,602

 

Porcupine

55

 

 

1

 

 

 

 

 

 

 

 

 

 

7

 

 

63

 

 

73

 

 

881

 

Éléonore

61

 

 

 

 

2

 

 

 

 

6

 

 

 

 

14

 

 

83

 

 

67

 

 

1,248

 

Peñasquito

64

 

 

1

 

 

 

 

 

 

 

 

2

 

 

9

 

 

76

 

 

97

 

 

769

 

Other North America

 

 

 

 

2

 

 

3

 

 

 

 

 

 

 

 

5

 

 

 

 

 

North America

310

 

 

4

 

 

8

 

 

3

 

 

9

 

 

2

 

 

47

 

 

383

 

 

359

 

 

1,067

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Yanacocha

127

 

 

17

 

 

3

 

 

 

 

4

 

 

 

 

4

 

 

155

 

 

119

 

 

1,309

 

Merian

81

 

 

1

 

 

1

 

 

 

 

 

 

 

 

9

 

 

92

 

 

130

 

 

707

 

Cerro Negro

51

 

 

1

 

 

3

 

 

 

 

7

 

 

 

 

10

 

 

72

 

 

73

 

 

985

 

Other South America

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

2

 

 

 

 

 

South America

259

 

 

19

 

 

7

 

 

2

 

 

11

 

 

 

 

23

 

 

321

 

 

322

 

 

997

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Boddington

131

 

 

3

 

 

1

 

 

 

 

 

 

3

 

 

25

 

 

163

 

 

148

 

 

1,094

 

Tanami

65

 

 

 

 

2

 

 

 

 

 

 

 

 

20

 

 

87

 

 

120

 

 

728

 

Other Australia

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

4

 

 

 

 

 

Australia

196

 

 

3

 

 

3

 

 

4

 

 

 

 

3

 

 

45

 

 

254

 

 

268

 

 

949

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ahafo

81

 

 

2

 

 

 

 

 

 

1

 

 

 

 

17

 

 

101

 

 

96

 

 

1,055

 

Akyem

51

 

 

7

 

 

 

 

 

 

 

 

 

 

6

 

 

64

 

 

83

 

 

766

 

Other Africa

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

2

 

 

 

 

 

Africa

132

 

 

9

 

 

 

 

2

 

 

1

 

 

 

 

23

 

 

167

 

 

179

 

 

930

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nevada Gold Mines

243

 

 

3

 

 

6

 

 

3

 

 

5

 

 

2

 

 

46

 

 

308

 

 

332

 

 

927

 

Nevada

243

 

 

3

 

 

6

 

 

3

 

 

5

 

 

2

 

 

46

 

 

308

 

 

332

 

 

927

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate and Other

 

 

 

 

12

 

 

51

 

 

2

 

 

 

 

6

 

 

71

 

 

 

 

 

Total Gold

$

1,140

 

 

$

38

 

 

$

36

 

 

$

65

 

 

$

28

 

 

$

7

 

 

$

190

 

 

$

1,504

 

 

1,460

 

 

$

1,030

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold equivalent ounces – other metals (11)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Peñasquito

$

167

 

 

$

2

 

 

$

1

 

 

$

 

 

$

 

 

$

46

 

 

$

26

 

 

$

242

 

 

288

 

 

$

841

 

Boddington

25

 

 

 

 

 

 

 

 

 

 

2

 

 

5

 

 

32

 

 

31

 

 

1,035

 

Total Gold Equivalent Ounces

$

192

 

 

$

2

 

 

$

1

 

 

$

 

 

$

 

 

$

48

 

 

$

31

 

 

$

274

 

 

319

 

 

$

860

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated

$

1,332

 

 

$

40

 

 

$

37

 

 

$

65

 

 

$

28

 

 

$

55

 

 

$

221

 

 

$

1,778

 

 

 

 

 

(1)

Excludes Depreciation and amortization and Reclamation and remediation.

(2)

Includes by-product credits of $24 and excludes co-product revenues of $260.

(3)

Includes stockpile and leach pad inventory adjustments of $18 at Yanacocha and $6 at NGM.

(4)

Reclamation costs include operating accretion and amortization of asset retirement costs of $23 and $17, respectively, and exclude accretion and reclamation and remediation adjustments at former operating properties and historic mining operations that have entered the closure phase and have no substantive future economic value of $13 and $2, respectively.

(5)

Advanced projects, research and development and Exploration excludes development expenditures of $1 at CC&V, $1 at Porcupine, $1 at Peñasquito, $1 at Yanacocha, $1 at Merian, $4 at Cerro Negro, $8 at Other South America, $2 at Tanami, $2 at Other Australia, $5 at Ahafo, $2 at Akyem, $2 at Other Africa, $1 at NGM and $3 at Corporate and Other, totaling $34 related to developing new operations or major projects at existing operations where these projects will materially benefit the operation.

(6)

Other expense, net includes $3, $6, $4 and $7 of cash care and maintenance costs associated with our Musselwhite, Éléonore, Yanacocha and Cerro Negro sites, respectively, temporarily being placed into care and maintenance in response to the COVID-19 global pandemic, during the period March 31, 2020 that we would have continued to incur if the sites were not temporarily placed into care and maintenance.

(7)

Other expense, net is adjusted for Goldcorp transaction and integration costs of $16, settlement costs of $6, incremental costs of responding to the COVID-19 pandemic of $2 and restructuring and severance costs of $1.

(8)

Includes sustaining capital expenditures of $61 for North America, $23 for South America, $47 for Australia, $23 for Africa, $46 for Nevada and $6 for Corporate and Other, totaling $206 and excludes development capital expenditures, capitalized interest and the change in accrued capital totaling $122. The following are major development projects: Musselwhite Materials Handling, Éléonore Lower Mine Material Handling System, Quecher Main, Yanacocha Sulfides, Tanami Expansion 2, Ahafo North, Goldrush Complex, Turquoise Ridge joint venture 3rd shaft and Range Front Declines at Cortez.

(9)

Includes finance lease payments for sustaining projects of $15.

(10)

Per ounce measures may not recalculate due to rounding.

(11)

Gold equivalent ounces is calculated as pounds or ounces produced multiplied by the ratio of the other metals price to the gold price, using Gold ($1,200/oz.), Copper ($2.75/lb.), Silver ($16.00/oz.), Lead ($0.95/lb.) and Zinc ($1.20/lb.) pricing for 2020.

A reconciliation of the 2021 Gold AISC outlook to the 2021 Gold CAS outlook, 2021 Co-product AISC outlook to the 2021 Co-product CAS outlook are provided below. The estimates in the table below are considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by such sections and other applicable laws.

2021 Outlook – Gold (7)(8)

 

(in millions, except ounces and per ounce)

Outlook Estimate

Cost Applicable to Sales (1)(2)

$

4,750

 

Reclamation Costs (3)

150

 

Advanced Projects and Exploration (4)

150

 

General and Administrative (5)

230

 

Other Expense

20

 

Treatment and Refining Costs

50

 

Sustaining Capital (6)

870

 

Sustaining Finance Lease Payments

30

 

All-in Sustaining Costs

$

6,250

 

Ounces (000) Sold (9)

6,400

 

All-in Sustaining Costs per Oz

$

970

 

(1)

Excludes Depreciation and amortization and Reclamation and remediation.

(2)

Includes stockpile and leach pad inventory adjustments.

(3)

Reclamation costs include operating accretion and amortization of asset retirement costs.

(4)

Advanced Project and Exploration excludes non-sustaining advanced projects and exploration.

(5)

Includes stock based compensation.

(6)

Excludes development capital expenditures, capitalized interest and change in accrued capital.

(7)

The reconciliation is provided for illustrative purposes in order to better describe management’s estimates of the components of the calculation. Estimates for each component of the forward-looking All-in sustaining costs per ounce are independently calculated and, as a result, the total All-in sustaining costs and the All-in sustaining costs per ounce may not sum to the component ranges. While a reconciliation to the most directly comparable GAAP measure has been provided for 2021 AISC Gold and Co-Product Outlook on a consolidated basis, a reconciliation has not been provided on an individual site or project basis in reliance on Item 10(e)(1)(i)(B) of Regulation S-K because such reconciliation is not available without unreasonable efforts.

(8)

All values are presented on a consolidated basis for Newmont.

(9)

Consolidated production for Yanacocha and Merian is presented on a total production basis for the mine site and excludes production from Pueblo Viejo.

2021 Outlook – Co-Product (7)(8)

 

(in millions, except GEO and per GEO)

Outlook Estimate

Cost Applicable to Sales (1)(2)

$

790

 

Reclamation Costs (3)

10

 

Advanced Projects and Exploration (4)

10

 

General and Administrative (5)

30

 

Other Expense

 

Treatment and Refining Costs

160

 

Sustaining Capital (6)

130

 

Sustaining Finance Lease Payments

20

 

All-in Sustaining Costs

$

1,150

 

Co-Product GEO (000) Sold (9)

1,300

 

All-in Sustaining Costs per Co Product GEO

$

880

 

(1)

Excludes Depreciation and amortization and Reclamation and remediation.

(2)

Includes stockpile and leach pad inventory adjustments.

(3)

Reclamation costs include operating accretion and amortization of asset retirement costs.

(4)

Advanced Project and Exploration excludes non-sustaining advanced projects and exploration.

(5)

Includes stock based compensation.

(6)

Excludes development capital expenditures, capitalized interest and change in accrued capital.

(7)

The reconciliation is provided for illustrative purposes in order to better describe management’s estimates of the components of the calculation. Estimates for each component of the forward-looking All-in sustaining costs per ounce are independently calculated and, as a result, the total All-in sustaining costs and the All-in sustaining costs per ounce may not sum to the component ranges. While a reconciliation to the most directly comparable GAAP measure has been provided for 2021 AISC Gold and Co-Product Outlook on a consolidated basis, a reconciliation has not been provided on an individual site or project basis in reliance on Item 10(e)(1)(i)(B) of Regulation S-K because such reconciliation is not available without unreasonable efforts.

(8)

All values are presented on a consolidated basis for Newmont.

(9)

Co-Product GEO are all non-gold co-products (Peñasquito silver, zinc, lead, Boddington copper).

Net debt to Adjusted EBITDA ratio

Management uses net debt to Adjusted EBITDA as non-GAAP measures to evaluate the Company’s operating performance, including our ability to generate earnings sufficient to service our debt. Net debt to Adjusted EBITDA represents the ratio of the Company’s debt, net of cash and cash equivalents, to Adjusted EBITDA. Net debt to Adjusted EBITDA does not represent, and should not be considered an alternative to, net income (loss), operating income (loss), or cash flow from operations as those terms are defined by GAAP, and does not necessarily indicate whether cash flows will be sufficient to fund cash needs. Although Net Debt to Adjusted EBITDA and similar measures are frequently used as measures of operations and the ability to meet debt service requirements by other companies, our calculation of net debt to Adjusted EBITDA measure is not necessarily comparable to such other similarly titled captions of other companies. The Company believes that net debt to Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Management’s determination of the components of net debt to Adjusted EBITDA is evaluated periodically and based, in part, on a review of non-GAAP financial measures used by mining industry analysts. Net income (loss) attributable to Newmont stockholders is reconciled to Adjusted EBITDA as follows:

 

Three Months Ended

 

 

March 31, 2021

 

December 31, 2020

 

September 30, 2020

 

June 30, 2020

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Newmont stockholders

$

559

 

 

 

$

824

 

 

 

$

839

 

 

 

$

344

 

 

 

Net income (loss) attributable to noncontrolling interests

20

 

 

 

(60

)

 

 

17

 

 

 

3

 

 

 

Net loss (income) from discontinued operations

(21

)

 

 

(18

)

 

 

(228

)

 

 

68

 

 

 

Equity loss (income) of affiliates

(50

)

 

 

(70

)

 

 

(53

)

 

 

(29

)

 

 

Income and mining tax expense (benefit)

235

 

 

 

258

 

 

 

305

 

 

 

164

 

 

 

Depreciation and amortization

553

 

 

 

615

 

 

 

592

 

 

 

528

 

 

 

Interest expense, net

74

 

 

 

73

 

 

 

75

 

 

 

78

 

 

 

EBITDA

1,370

 

 

 

1,622

 

 

 

1,547

 

 

 

1,156

 

 

 

EBITDA Adjustments:

 

 

 

 

 

 

 

 

Change in fair value of investments

110

 

 

 

(61

)

 

 

(57

)

 

 

(227

)

 

 

Loss (gain) on asset and investment sales

(43

)

 

 

(84

)

 

 

(1

)

 

 

1

 

 

 

Reclamation and remediation charges

10

 

 

 

213

 

 

 

 

 

 

 

 

 

Restructuring and severance

5

 

 

 

6

 

 

 

9

 

 

 

2

 

 

 

Settlement costs

3

 

 

 

24

 

 

 

26

 

 

 

2

 

 

 

COVID-19 specific costs

1

 

 

 

25

 

 

 

32

 

 

 

33

 

 

 

Impairment of long-lived and other assets

1

 

 

 

20

 

 

 

24

 

 

 

5

 

 

 

Pension settlements and curtailments

 

 

 

7

 

 

 

83

 

 

 

2

 

 

 

Goldcorp transaction and integration costs

 

 

 

 

 

 

 

 

 

7

 

 

 

Loss on debt extinguishment

 

 

 

 

 

 

 

 

 

3

 

 

 

Adjusted EBITDA

1,457

 

 

 

1,772

 

 

 

1,663

 

 

 

984

 

 

 

12 month trailing Adjusted EBITDA

$

5,876

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Debt

$

6,030

 

 

 

 

 

 

 

 

 

Lease and other financing obligations

684

 

 

 

 

 

 

 

 

 

Less: Cash and cash equivalents

5,518

 

 

 

 

 

 

 

 

 

Total net debt

$

1,196

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net debt to adjusted EBITDA

0.2

 

 

 

 

 

 

 

 

 

Net average realized price per ounce/ pound

Average realized price per ounce/ pound are non-GAAP financial measures. The measures are calculated by dividing the net consolidated gold, copper, silver, lead and zinc sales by the consolidated gold ounces, copper pounds, silver ounces, lead pounds and zinc pounds sold, respectively. These measures are calculated on a consistent basis for the periods presented on a consolidated basis. Average realized price per ounce/ pound statistics are intended to provide additional information only, do not have any standardized meaning prescribed by GAAP and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The measures are not necessarily indicative of operating profit or cash flow from operations as determined under GAAP. Other companies may calculate these measures differently.

The following tables reconcile these non-GAAP measures to the most directly comparable GAAP measure:

 

Three Months Ended

March 31,

 

2021

 

2020

Consolidated gold sales, net

$

2,482

 

 

$

2,321

 

Consolidated copper sales, net

52

 

 

21

 

Consolidated silver sales, net

168

 

 

123

 

Consolidated lead sales, net

44

 

 

39

 

Consolidated zinc sales, net

126

 

 

77

 

Total sales

$

2,872

 

 

$

2,581

 

 

Three Months Ended March 31, 2021

 

Gold

 

Copper

 

Silver

 

Lead

 

Zinc

 

(ounces)

 

(pounds)

 

(ounces)

 

(pounds)

 

(pounds)

Consolidated sales:

 

 

 

 

 

 

 

 

 

Gross before provisional pricing and streaming impact

$

2,523

 

 

 

$

48

 

 

 

$

163

 

 

 

$

59

 

 

 

$

151

 

 

Provisional pricing mark-to-market

(28

)

 

 

5

 

 

 

 

 

 

(13

)

 

 

 

 

Silver streaming amortization

 

 

 

 

 

 

21

 

 

 

 

 

 

 

 

Gross after provisional pricing and streaming impact

2,495

 

 

 

53

 

 

 

184

 

 

 

46

 

 

 

151

 

 

Treatment and refining charges

(13

)

 

 

(1

)

 

 

(16

)

 

 

(2

)

 

 

(25

)

 

Net

$

2,482

 

 

 

$

52

 

 

 

$

168

 

 

 

$

44

 

 

 

$

126

 

 

Consolidated ounces (thousands)/ pounds (millions) sold

1,417

 

 

 

12

 

 

 

8,531

 

 

 

50

 

 

 

119

 

 

Average realized price (per ounce/pound)(1):

 

 

 

 

 

 

 

 

 

Gross before provisional pricing and streaming impact

$

1,780

 

 

 

$

3.94

 

 

 

$

19.15

 

 

 

$

1.18

 

 

 

$

1.27

 

 

Provisional pricing mark-to-market

(20

)

 

 

0.36

 

 

 

0.05

 

 

 

(0.27

)

 

 

 

 

Silver streaming amortization

 

 

 

 

 

 

2.44

 

 

 

 

 

 

 

 

Gross after provisional pricing and streaming impact

1,760

 

 

 

4.30

 

 

 

21.64

 

 

 

0.91

 

 

 

1.27

 

 

Treatment and refining charges

(9

)

 

 

(0.10

)

 

 

(1.91

)

 

 

(0.03

)

 

 

(0.21

)

 

Net

$

1,751

 

 

 

$

4.20

 

 

 

$

19.73

 

 

 

$

0.88

 

 

 

$

1.06

 

 

(1)

Per ounce/pound measures may not recalculate due to rounding.

 

Three Months Ended March 31, 2020

 

Gold

 

Copper

 

Silver

 

Lead

 

Zinc

 

(ounces)

 

(pounds)

 

(ounces)

 

(pounds)

 

(pounds)

Consolidated sales:

 

 

 

 

 

 

 

 

 

Gross before provisional pricing and streaming impact

$

2,316

 

 

$

34

 

 

$

118

 

 

$

50

 

 

$

120

 

Provisional pricing mark-to-market

12

 

 

(11)

 

 

(9)

 

 

(2)

 

 

(13)

 

Silver streaming amortization

 

 

 

 

21

 

 

 

 

 

Gross after provisional pricing and streaming impact

2,328

 

 

23

 

 

130

 

 

48

 

 

107

 

Treatment and refining charges

(7)

 

 

(2)

 

 

(7)

 

 

(9)

 

 

(30)

 

Net

$

2,321

 

 

$

21

 

 

$

123

 

 

$

39

 

 

$

77

 

Consolidated ounces (thousands)/ pounds (millions) sold

1,460

 

13

 

8,678

 

60

 

124

Average realized price (per ounce/pound)(1):

 

 

 

 

 

 

 

 

 

Gross before provisional pricing and streaming impact

$

1,587

 

 

$

2.48

 

 

$

13.59

 

 

$

0.83

 

 

$

0.97

 

Provisional pricing mark-to-market

9

 

 

(0.81)

 

 

(1.00)

 

 

(0.03)

 

 

(0.11)

 

Silver streaming amortization

 

 

 

 

2.39

 

 

 

 

 

Gross after provisional pricing and streaming impact

1,596

 

 

1.67

 

 

14.98

 

 

0.80

 

 

0.86

 

Treatment and refining charges

(5)

 

 

(0.11)

 

 

(0.85)

 

 

(0.16)

 

 

(0.24)

 

Net

$

1,591

 

 

$

1.56

 

 

$

14.13

 

 

$

0.64

 

 

$

0.62

 

(1)

Per ounce/pound measures may not recalculate due to rounding.

Gold by-product metrics

Copper, sliver, lead and zinc are by-products often obtained during the process of extracting and processing the primary ore-body. In our GAAP Consolidated Financial Statements, the value of these by-products is recorded as a credit to our CAS and the value of the primary ore is recorded as Sales. In certain instances, copper, silver, lead and zinc are co-products, or a significant resource in the primary ore-body, and the revenue is recorded as Sales in our GAAP Consolidated Financial Statements.

Gold by-product metrics are non-GAAP financial measures that serve as a basis for comparing the Company’s performance with certain competitors. As Newmont’s operations are primarily focused on gold production, “Gold by-product metrics” were developed to allow investors to view Sales, CAS per ounce and AISC per ounce calculations that classify all copper, silver, lead and zinc production as a by-product, even when copper, silver, lead or zinc is a significant resource in the primary ore-body. These metrics are calculated by subtracting copper, silver, lead and zinc sales recognized from Sales and including these amounts as offsets to CAS.

Gold by-product metrics are calculated on a consistent basis for the periods presented on a consolidated basis. These metrics are intended to provide supplemental information only, do not have any standardized meaning prescribed by GAAP and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. Other companies may calculate these measures differently as a result of differences in the underlying accounting principles, policies applied and in accounting frameworks, such as in IFRS.

The following tables reconcile these non-GAAP measures to the most directly comparable GAAP measures:

 

Three Months Ended

March 31,

 

2021

 

2020

Consolidated gold sales, net

$

2,482

 

 

$

2,321

 

Consolidated other metal sales, net

390

 

 

260

 

Sales

$

2,872

 

 

$

2,581

 

 

 

 

 

Costs applicable to sales

$

1,247

 

 

$

1,332

 

Less: Consolidated other metal sales, net

(390)

 

 

(260)

 

By-Product costs applicable to sales

$

857

 

 

$

1,072

 

Gold sold (thousand ounces)

1,417

 

 

1,460

 

Total Gold CAS per ounce (by-product) (1)

$

605

 

 

$

734

 

 

 

 

 

Total AISC

$

1,740

 

 

$

1,778

 

Less: Consolidated other metal sales, net

(390)

 

 

(260)

 

By-Product AISC

$

1,350

 

 

$

1,518

 

Gold sold (thousand ounces)

1,417

 

 

1,460

 

Total Gold AISC per ounce (by-product) (1)

$

953

 

 

$

1,040

 

(1)

Per ounce measures may not recalculate due to rounding.

Conference Call Information

A conference call will be held on Thursday, April 29, 2021 at 10:00 a.m. Eastern Time (8:00 a.m. Mountain Time); it will also be carried on the Company’s website.

Conference Call Details

Dial-In Number

 

855.209.8210

Intl Dial-In Number

 

412.317.5213

Conference Name

 

Newmont

Replay Number

 

877.344.7529

Intl Replay Number

 

412.317.0088

Replay Access Code

 

10153505

Webcast Details

Title: Newmont First Quarter 2021 Earnings Conference Call

URL: https://event.on24.com/wcc/r/3079740/2D57F80FC3C94212FDC3597AE9AFB06C

The first quarter 2021 results will be available before the market opens on Thursday, April 29, 2021 on the “Investor Relations” section of the Company’s website, www.newmont.com. Additionally, the conference call will be archived for a limited time on the Company’s website.

About Newmont

Newmont is the world’s leading gold company and a producer of copper, silver, zinc and lead. The Company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in North America, South America, Australia and Africa. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social and governance practices. The Company is an industry leader in value creation, supported by robust safety standards, superior execution and technical expertise. Newmont was founded in 1921 and has been publicly traded since 1925.

Cautionary Statement Regarding Forward Looking Statements, Including Outlook:

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by such sections and other applicable laws. Where a forward-looking statement expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis. However, such statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by the forward-looking statements. Forward-looking statements often address our expected future business and financial performance and financial condition; and often contain words such as “anticipate,” “intend,” “plan,” “will,” “would,” “estimate,” “expect,” “believe,” “target,” “indicative,” “preliminary,” or “potential.” Forward-looking statements in this news release may include, without limitation, (i) estimates of future production and sales, including production outlook, average future production, upside potential and indicative production profiles; (ii) estimates of future costs applicable to sales and all-in sustaining costs; (iii) estimates of future capital expenditures, including development and sustaining capital; (iv) estimates of future cost reductions, full potential savings, value creation, improvements, synergies and efficiencies; (v) expectations regarding the Tanami Expansion 2, Ahafo North and Yanacocha Sulfides projects, as well as the development, growth and exploration potential of the Company’s other operations, projects and investments, including, without limitation, returns, IRR, schedule, approval and decision dates, mine life and mine life extensions, commercial start, first production, average production, average costs, impacts of improvement or expansion projects and upside potential; (vi) expectations regarding future investments or divestitures; (vii) expectations regarding free cash flow, and returns to stockholders, including with respect to future dividends and future share repurchases; (viii) expectations regarding future mineralization, including, without limitation, expectations regarding reserves and recoveries; (ix) estimates of future closure costs and liabilities; (x) expectations regarding the timing and/or likelihood of future borrowing, future debt repayment, financial flexibility and cash flow; and (xi) expectations regarding the impact of the Covid-19 pandemic and vaccine. Estimates or expectations of future events or results are based upon certain assumptions, which may prove to be incorrect. Such assumptions, include, but are not limited to: (i) there being no significant change to current geotechnical, metallurgical, hydrological and other physical conditions; (ii) permitting, development, operations and expansion of operations and projects being consistent with current expectations and mine plans, including, without limitation, receipt of export approvals; (iii) political developments in any jurisdiction in which the Company operates being consistent with its current expectations; (iv) certain exchange rate assumptions being approximately consistent with current levels; (v) certain price assumptions for gold, copper, silver, zinc, lead and oil; (vi) prices for key supplies being approximately consistent with current levels; (vii) the accuracy of current mineral reserve and mineralized material estimates; and (viii) other planning assumptions. Uncertainties relating to the impacts of Covid-19, include, without limitation, general macroeconomic uncertainty and changing market conditions, changing restrictions on the mining industry in the jurisdictions in which we operate, the ability to operate following changing governmental restrictions on travel and operations (including, without limitation, the duration of restrictions, including access to sites, ability to transport and ship doré, access to processing and refinery facilities, impacts to international trade, impacts to supply chain, including price, availability of goods, ability to receive supplies and fuel, impacts to productivity and operations in connection with decisions intended to protect the health and safety of the workforce, their families and neighboring communities), the impact of additional waves or variations of Covid, and the availability and impact of Covid vaccinations in the areas and countries in which we operate. Investors are reminded that only the first quarter has been declared by the Board of Directors at this time. Future dividends for 2021 have not yet been approved or declared by the Board of Directors, and an annualized dividend payout or dividend yield has not been declared by the Board. Management’s expectations with respect to future dividends are “forward-looking statements” and the Company’s dividend framework is non-binding. The declaration and payment of future dividends remain at the discretion of the Board of Directors and will be determined based on Newmont’s financial results, balance sheet strength, cash and liquidity requirements, future prospects, gold and commodity prices, and other factors deemed relevant by the Board. Investors are also cautioned that the extent to which the Company repurchases its shares, and the timing of such repurchases, will depend upon a variety of factors, including trading volume, market conditions, legal requirements, business conditions and other factors. The repurchase program may be discontinued at any time, and the program does not obligate the Company to acquire any specific number of shares of its common stock or to repurchase the full authorized amount during the authorization period. Consequently, the Board of Directors may revise or terminate such share repurchase authorization in the future. For a more detailed discussion of risks and other factors that might impact future looking statements, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (the “SEC”), under the heading “Risk Factors”, filed with the SEC, available on the SEC website or www.newmont.com. The Company does not undertake any obligation to release publicly revisions to any “forward-looking statement,” including, without limitation, outlook, to reflect events or circumstances after the date of this news release, or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws. Investors should not assume that any lack of update to a previously issued “forward-looking statement” constitutes a reaffirmation of that statement. Continued reliance on “forward-looking statements” is at investors’ own risk.

Notice for U.S. Investors:

The terms “resources” and “Measured, Indicated and Inferred resources” are used in this news release. Investors are advised that the SEC does not recognize these terms and “resources” have not been prepared in accordance with Industry Guide 7. Newmont has determined that such “resources” would be substantively the same as those prepared using the Guidelines established by the Society of Mining, Metallurgy and Exploration (SME) and defined as “Mineral Resource”. Estimates of resources are subject to further exploration and development, are subject to additional risks, and no assurance can be given that they will eventually convert to future reserves. Inferred Resources, in particular, have a great amount of uncertainty as to their existence and their economic and legal feasibility. Investors are cautioned not to assume that any part or all of the Inferred Resource exists, or is economically or legally mineable. Investors are reminded that even if significant mineralization is discovered and converted to reserves, during the time necessary to ultimately move such mineralization to production the economic feasibility of production may change. US investors are encouraged to refer to the “Proven and Probable Reserve” tables contained herein for reserves prepared in compliance with the SEC’s Industry Guide 7 and “Mineralized Material” tables, available at www.newmont.com and included in the Company’s Form 10-K, filed on February 18, 2021, on www.sec.gov. Additional information on the Company’s resource estimates can be found at www.newmont.com/operations-and-projects/reserves-and-resources.

Media Contact

Courtney Boone

303.837.5159

[email protected]

Investor Contact

Eric Colby

303.837.5724

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Mining/Minerals Natural Resources

MEDIA:

Logo
Logo

Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

Prompted by positive interim analysis data Can-Fite accelerates patient enrollment

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that 75% of patients have been enrolled in its Phase III Comfort™ study designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to Apremilast (Otezla®) in patients with moderate to severe plaque psoriasis. The Company expects to complete enrollment in Q3 2021 and report topline results in Q4 2021.

Recently, the Company conducted an interim analysis with an Independent Data Monitoring Committee (IDMC) which recommended based on the positive data and favorable safety profile to continue patient enrollment. The randomized, double blind study is being conducted in Europe, Israel, and Canada. The study’s primary endpoint is the proportion of patients who achieve a PASI score response of ≥75% (PASI 75) vs. placebo at week 16. Secondary endpoints include non-inferiority to Otezla® in weeks 16 and 32.

“Can-Fite’s lead drug candidate offers several potential key benefits over psoriasis treatments currently on the market. It provides easy administration for patients who tend to prefer oral medications over injectables and has demonstrated a favorable safety profile and positive clinical effect in trials,” stated Can-Fite CEO Dr. Pnina Fishman.

Piclidenoson has been out-licensed for the indication of psoriasis in Canada, South Korea, Spain, Austria, Switzerland, Central Eastern European (CEE) countries, Hong Kong, Macau, Taiwan, and China. Can-Fite has received over $20 million in up-front and milestone payments from its distribution agreements to date. According to iHealthcareAnalyst, the psoriasis therapeutic market is estimated to reach $11.3 billion by 2025.

About Piclidenoson

Piclidenoson is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic index demonstrated in Phase II clinical studies. It is currently being evaluated in a multinational Phase III study as a treatment for moderate to severe psoriasis and a Phase II U.S. study for the treatment of moderate to severe COVID-19.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite’s liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the impact of the COVID-19 pandemic; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite’s filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Can-Fite BioPharma

Motti Farbstein

[email protected]

+972-3-9241114

KEYWORDS: United States North America Israel Middle East

INDUSTRY KEYWORDS: Oncology Health Other Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Stericycle, Inc. Reports Results For the First Quarter 2021

BANNOCKBURN, Ill., April 29, 2021 (GLOBE NEWSWIRE) — Stericycle, Inc. (Nasdaq: SRCL) today reported results for the first quarter ended March 31, 2021.

Revenues for the first quarter were $668.0 million, a decrease of 14.9% compared to $785.0 million in the first quarter of last year, primarily due to the impact of divestitures. Organic revenues increased 0.9% when excluding the impact of divestitures and foreign exchange rate. Income from operations was $59.1 million, compared to a loss from operations of $30.4 million in the first quarter of last year. Net income was $26.1 million, or $0.28 diluted earnings per share, compared to a net loss of $20.1 million, or $0.22 diluted loss per share, in the first quarter of last year. Adjusted income from operations was $110.0 million, compared to $93.8 million in the first quarter of 2020. Adjusted diluted earnings per share was $0.71, compared to $0.52 in the first quarter of last year. Cash flow from operations for the three months ended March 31, 2021 was $62.6 million, compared to $82.1 million for the same period in 2020. Free cash flow for the three months ended March 31, 2021 was $37.9 million, compared to $42.5 million for the same period in 2020.

KEY BUSINESS HIGHLIGHTS:

  • Regulated Waste and Compliance Services (“RWCS”) organic revenues grew 6.0% in the first quarter compared to the first quarter of 2020.
  • Adjusted income from operations as a percentage of revenues improved 460 basis points in the first quarter compared to the first quarter of 2020.
  • Net debt was reduced by $38.3 million in the first quarter, decreasing total net debt to approximately $1.70 billion. The credit agreement defined debt leverage ratio was reduced to 3.28 times as of March 31, 2021, compared to 4.50 times as of March 31, 2020.

“Our first quarter performance builds on the commercial and operational momentum we achieved in 2020,” said Cindy J. Miller, Chief Executive Officer. “Regulated Waste and Compliance Services organic revenues expanded further this quarter, benefiting from our quality of revenue initiatives and the value of our essential services during the pandemic.”

FIRST QUARTER FINANCIAL RESULTS


U.S. Generally Accepted Accounting Principles (GAAP) Results

  • Revenues in the first quarter were $668.0 million, compared to $785.0 million in the first quarter of last year. Of the $117.0 million decline, the impact of divestitures was $135.0 million and Secure Information Destruction (“SID”) revenues accounted for $26.8 million, reflecting pandemic related business disruption. These declines were offset by RWCS organic revenue growth of $34.1 million and the positive impact of foreign exchange rates of $10.7 million.
  • Income from operations in the first quarter was $59.1 million, compared to a loss from operations of $30.4 million in the first quarter of last year. The $89.5 million increase was primarily due to the first quarter of 2021 having no net divestiture losses compared to the first quarter of 2020 having net divestiture losses of $58.3 million and lower operating expenditures of $31.4 million in the first quarter of 2021.
  • Net income in the first quarter was $26.1 million, or $0.28 diluted earnings per share, compared to a net loss of $20.1 million, or $0.22 diluted loss per share, in the first quarter of last year. The difference was related to higher income from operations of $89.5 million, as explained above, and lower interest expense of $6.6 million. These were partially offset by an increase in income tax expense of $52.2 million compared to the first quarter of 2020, primarily as a result of a non-recurring U.S. Cares Act tax benefit of $39.4 million in the first quarter of 2020 and higher taxable income generated in the first quarter of 2021.
  • Cash flow from operations for the first quarter ended March 31, 2021 was $62.6 million, compared to $82.1 million in 2020. The decrease of $19.5 million was primarily driven by an annual incentive compensation payout of $38.6 million in 2021 and higher accounts receivables of $9.2 million driven by increased revenues. These were partially offset by lower interest payments of $15.6 million, primarily as a result of lower debt balances and improved operating performance and other working capital changes of $12.7 million.
  • Cash paid for capital expenditures for the first quarter ended March 31, 2021 was $24.7 million, compared to $39.6 million for the first quarter ended March 31, 2020, primarily driven by $22.0 million less in ERP capital expenditures in 2021 compared to the first quarter of 2020 and the timing of planned 2021 capital expenditures.


Non-GAAP Results

  • For the first quarter of 2021, organic revenues increased 0.9%, which excludes the impact of divestitures and foreign exchange rates. In the first quarter, organic revenues of RWCS grew 6.0%, while SID declined 12.3%, both impacted by the pandemic.
  • Adjusted income from operations was $110.0 million, compared to $93.8 million in the first quarter of last year. Adjusted income from operations as a percent of revenues improved 460 basis points. As a percentage of revenues, lower SG&A contributed approximately 280 basis points of the improvement, quality of revenue and operational efficiency initiatives contributed approximately 200 basis points, and divestitures of lower margin businesses contributed approximately 120 basis points. These improvements were partially offset by increased International RWCS third-party disposal costs of approximately 90 basis points and severe weather impact in North America of approximately 60 basis points.
  • Adjusted diluted earnings per share was $0.71, compared to $0.52 in the first quarter of last year. The $0.19 improvement was primarily due to higher adjusted income from operations of $0.18 and lower interest expense and other of $0.06, and net favorable impact from foreign exchange rates of $0.01, which were partially offset by divestitures of $0.06.
  • Free cash flow for the first quarter ended March 31, 2021 was $37.9 million, compared to $42.5 million for the first quarter ended March 31, 2020. The $4.6 million decrease was due to lower cash flow from operations, partially offset by lower capital expenditures, as described above.

CONFERENCE CALL INFORMATION

Stericycle is holding its first quarter earnings conference call on Thursday, April 29, 2021 at 8:00 a.m. central time.  Dial (888) 317-6003 in the U.S., (866) 605-3851 in Canada, or (412) 317-6061 if outside the U.S./Canada at least 10 minutes before the call begins. Upon dialing the number, you will be prompted to enter the Elite Entry Number 2098768. To access presentation materials, listen to the call via an internet webcast, or access an audio replay of the call, visit investors.stericycle.com.

NON-GAAP FINANCIAL MEASURES

Non-GAAP financial measures are reconciled to the most comparable U.S. GAAP measures in the schedules attached hereto.

ABOUT STERICYCLE

Stericycle, Inc., (Nasdaq: SRCL) is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people, promotes health and safeguards the environment. Stericycle serves customers in the U.S. and 17 other countries worldwide with solutions for regulated waste and compliance services, secure information destruction, and patient engagement. For more information about Stericycle, please visit stericycle.com.

SAFE HARBOR STATEMENT

This document may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. When we use words such as “believes”, “expects”, “anticipates”, “estimates”, “may”, “plan”, “will”, “goal”, or similar expressions, we are making forward-looking statements. Forward-looking statements are prospective in nature and are not based on historical facts, but rather on current expectations and projections of our management about future events and are therefore subject to risks and uncertainties, which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Factors that could cause such differences include, among others, developments in the COVID-19 pandemic and the resulting impact on the results of operations, long-term remote work arrangements, which may adversely affect our business, precautions we have taken to safeguard the health and safety of our team members which may make certain of our business processes less efficient, measures taken by governmental authorities to prevent the spread of the COVID-19 virus which could disrupt our supply chain, result in disruptions in transportation services and restrictions on the ability of our team members to travel, result in temporary closure of our facilities or the facilities of our customers and suppliers, affect the volume of paper processed by our secure information destruction business and the revenue generated from the sale of SOP, disruptions in our relationships with our team members as a result of certain cost-saving measures, an economic slowdown in the U.S. and other countries resulting from the outbreak of the COVID-19 virus, changing market conditions in the healthcare industry, competition and demand for services in the regulated waste and secure information destruction industries, SOP pricing volatility, foreign exchange rate volatility in the jurisdictions in which we operate, changes in governmental regulation of the collection, transportation, treatment and disposal of regulated waste or the proper handling and protection of personal and confidential information, the level of government enforcement of regulations governing regulated waste collection and treatment or the proper handling and protection of personal and confidential information, decreases in the volume of regulated wastes or personal and confidential information collected from customers, the ability to implement our new ERP system, disruptions in or attacks on information technology systems, charges related to portfolio optimization or the failure of divestitures to achieve the desired results, failure to consummate transactions with respect to non-core businesses, the obligations to service substantial indebtedness and comply with the covenants and restrictions contained in our credit agreements and notes, a downgrade in our credit rating resulting in an increase in interest expense, political, economic, inflationary and other risks related to our foreign operations, the outcome of pending or future litigation or investigations including with respect to the U.S. Foreign Corrupt Practices Act, weather and environmental changes related to climate change, requirements of customers and investors for net carbon zero emissions strategies, and the introduction of regulations for greenhouse gases, which could negatively affect our costs to operate, failure to maintain an effective system of internal control over financial reporting, delays or failures in implementing remediation efforts with respect to potential future material weaknesses, as well as other factors described in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Forms 10-Q. As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends. We disclaim any obligation to update or revise any forward-looking or other statements contained herein other than in accordance with legal and regulatory obligations.

FOR FURTHER INFORMATION CONTACT:

Stericycle Investor Relations 847-607-2012

STERICYCLE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

In millions, except per share data
  Three Months Ended March 31,
  2021   % Revenues   2020   % Revenues   % Change
Revenues $ 668.0       100.0   %   $ 785.0       100.0   %   (14.9 ) %
Cost of revenues 406.6       60.9   %   498.4       63.5   %   (18.4 ) %
Gross profit 261.4       39.1   %   286.6       36.5   %   (8.8 ) %
Selling, general and administrative expenses 202.3       30.3   %   258.7       33.0   %   (21.8 ) %
Divestiture losses (gains), net         %   58.3       7.4   %   (100.0 ) %
Income (loss) from operations 59.1       8.8   %   (30.4 )     (3.9 ) %   (294.4 ) %
Interest expense, net (18.4 )     (2.8 ) %   (25.0 )     (3.2 ) %   (26.4 ) %
Other expense, net (0.7 )     (0.1 ) %   (2.9 )     (0.4 ) %   (75.9 ) %
Income (loss) before income taxes 40.0       6.0   %   (58.3 )     (7.4 ) %   (168.6 ) %
Income tax (expense) benefit (13.8 )     (2.1 ) %   38.4       4.9   %   (135.9 ) %
Net income (loss) 26.2       3.9   %   (19.9 )     (2.5 ) %   (231.7 ) %
Net income attributable to noncontrolling interests (0.1 )       %   (0.2 )       %   (50.0 ) %
Net income (loss) attributable to Stericycle, Inc. common shareholders $ 26.1       3.9   %   $ (20.1 )     (2.6 ) %   (229.9 ) %
Earnings (loss) per common share attributable to Stericycle, Inc. common shareholders:                  
Basic $ 0.29           $ (0.22 )         (231.8 ) %
Diluted $ 0.28           $ (0.22 )         (227.3 ) %
Weighted average number of common shares outstanding:                  
Basic 91.6           91.3            
Diluted 92.0           91.3            
                           
nm – percentage change not meaningful                          

STATISTICS – U.S. GAAP AND NON-GAAP ADJUSTED FINANCIAL MEASURES

(Unaudited)

In millions, except per share data              
  Three Months Ended March 31,
  2021   % Revenues   2020   % Revenues

Statistics – U.S. GAAP
             
Effective tax rate   34.5 %         65.9 %    

Statistics – Adjusted 



(1)

                     
Adjusted gross profit $ 261.4     39.1 %   $ 286.6     36.5 %
Adjusted selling, general and administrative expenses $ 151.4     22.7 %   $ 192.8     24.6 %
Adjusted income from operations $ 110.0     16.5 %   $ 93.8     11.9 %
Adjusted EBITDA $ 135.2     20.2 %   $ 121.2     15.4 %
Adjusted net income attributable to common shareholders $ 64.9     9.7 %   $ 47.1     6.0 %
Adjusted effective tax rate   28.5 %         28.4 %    
Adjusted diluted earnings per share $ 0.71         $ 0.52      
Adjusted diluted shares outstanding   92.0           91.5      

(1) Adjusted financial measures are Non-GAAP measures and exclude adjusting items as described and reconciled to comparable U.S. GAAP financial measures in the Reconciliation of U.S. GAAP to Non-GAAP Financial Measures contained in this Press Release.





STERICYCLE, INC.


CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

In millions, except per share data      
  March 31, 2021   December 31, 2020
ASSETS      
Current Assets:      
Cash and cash equivalents $ 50.0       $ 53.3    
Accounts receivable, less allowance for doubtful accounts of $50.5 in 2021 and $56.2 in 2020 388.3       380.7    
Prepaid expenses 48.3       63.0    
Other current assets 50.6       55.5    
Total Current Assets 537.2       552.5    
Property, plant and equipment, less accumulated depreciation of $642.0 in 2021 and $629.7 in 2020 702.4       701.3    
Operating lease right-of-use assets 373.5       365.0    
Goodwill 2,811.3       2,819.3    
Intangible assets, less accumulated amortization of $669.3 in 2021 and $641.6 in 2020 1,054.0       1,087.4    
Other assets 53.0       56.4    
Total Assets $ 5,531.4       $ 5,581.9    
LIABILITIES AND EQUITY      
Current Liabilities:      
Current portion of long-term debt $ 88.6       $ 91.0    
Bank overdrafts 4.3          
Accounts payable 195.1       181.2    
Accrued liabilities 245.2       289.4    
Operating lease liabilities 87.4       86.2    
Other current liabilities 53.4       49.3    
Total Current Liabilities 674.0       697.1    
Long-term debt, net 1,651.0       1,689.1    
Long-term operating lease liabilities 305.3       299.0    
Deferred income taxes 375.9       380.4    
Long-term taxes payable 18.1       22.7    
Other liabilities 58.3       59.2    
Total Liabilities 3,082.6       3,147.5    
       
Commitments and Contingencies          
       
EQUITY      
Common stock (par value $0.01 per share, 120.0 shares authorized, 91.8 and 91.6 issued and outstanding in 2021 and 2020, respectively) 0.9       0.9    
Additional paid-in capital 1,235.9       1,234.0    
Retained earnings 1,408.7       1,382.6    
Accumulated other comprehensive loss (200.3 )     (187.4 )  
Total Stericycle, Inc.’s Equity 2,445.2       2,430.1    
Noncontrolling interests 3.6       4.3    
Total Equity 2,448.8       2,434.4    
Total Liabilities and Equity $ 5,531.4       $ 5,581.9    





STERICYCLE, INC.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

In millions      
  Three Months Ended March 31,
  2021   2020
OPERATING ACTIVITIES:      
Net income (loss) $ 26.2       $ (19.9 )  
Adjustments to reconcile net income (loss) to net cash from operating activities:      
Depreciation 25.5       28.0    
Intangible amortization 29.8       31.9    
Stock-based compensation expense 5.1       5.1    
Deferred income taxes (2.1 )     (0.4 )  
Divestiture losses (gains), net       58.3    
Asset impairments, loss (gain) on disposal of property plant and equipment and other charges       3.9    
Other, net 1.9       0.1    
Changes in operating assets and liabilities, net of the effects of divestitures:      
Accounts receivable (10.4 )     (1.2 )  
Prepaid expenses 14.4       (32.7 )  
Accounts payable 11.2       9.3    
Accrued liabilities (34.2 )     (7.7 )  
Other assets and liabilities (4.8 )     7.4    
Net cash from operating activities 62.6       82.1    
INVESTING ACTIVITIES:      
Capital expenditures (24.7 )     (39.6 )  
Other, net 0.2       (0.5 )  
Net cash from investing activities (24.5 )     (40.1 )  
FINANCING ACTIVITIES:      
Repayments of long-term debt and other obligations (6.3 )     (6.7 )  
Repayments of foreign bank debt (0.1 )     (2.6 )  
Repayment of term loan (11.9 )     (43.8 )  
Proceeds from senior credit facility 269.3       343.6    
Repayment of senior credit facility (288.8 )     (327.4 )  
Proceeds from bank overdrafts, net 4.3       1.2    
Payments of capital lease obligations (0.9 )     (1.3 )  
Payments of debt issuance costs       (1.4 )  
Proceeds from issuance of common stock, net of (payments of) taxes from withheld shares (5.1 )     (1.2 )  
Payments to noncontrolling interest (0.6 )        
Net cash from financing activities (40.1 )     (39.6 )  
Effect of exchange rate changes on cash and cash equivalents (1.3 )     (1.1 )  
Net change in cash and cash equivalents (3.3 )     1.3    
Cash and cash equivalents at beginning of period 53.3       34.7    
Cash and cash equivalents at end of period $ 50.0       $ 36.0    
       
SUPPLEMENTAL CASH FLOW INFORMATION:      
Interest paid during the period, net of capitalized interest $ 20.0       $ 35.6    
Income taxes paid (refunded), net during the period $ 1.9       $ 0.4    
Capital expenditures in Accounts payable $ 15.5       $ 33.1    
Free Cash Flow (1) $ 37.9       $ 42.5    

(1) Free Cash Flow is calculated as Net cash from operating activities less Capital expenditures.





Table 1–A: REVENUES CHANGES BY SERVICE AND SEGMENT (UNAUDITED) –


THREE MONTHS ENDED MARCH 31, 2021 AND 2020

  Three Months Ended March 31,
  In millions       Components of Change (%)
  2021   2020   Change ($)   Change (%)   Organic
Growth


(1)
  Divestitures   Foreign Exchange

(2)
Revenue by Service                          
Regulated Waste and Compliance Services (3) $ 473.6     $ 566.9     $ (93.3 )   (16.5 ) %   6.0   %   (23.8 ) %   1.3 %
Secure Information Destruction Services 194.4     218.1     (23.7 )   (10.9 ) %   (12.3 ) %     %   1.4 %
Total Revenues $ 668.0     $ 785.0     $ (117.0 )   (14.9 ) %   0.9   %   (17.2 ) %   1.4 %
North America                          
Regulated Waste and Compliance Services (3) $ 366.8     $ 468.6     $ (101.8 )   (21.7 ) %   3.8   %   (25.8 ) %   0.3 %
Secure Information Destruction Services 166.9     186.0     (19.1 )   (10.3 ) %   (10.8 ) %     %   0.5 %
Total North America Segment $ 533.7     $ 654.6     $ (120.9 )   (18.5 ) %   (0.3 ) %   (18.5 ) %   0.3 %
International                          
Regulated Waste and Compliance Services (3) $ 106.8     $ 98.3     $ 8.5     8.6   %   16.4   %   (14.3 ) %   6.5 %
Secure Information Destruction Services 27.5     32.1     (4.6 )   (14.3 ) %   (21.2 ) %     %   6.9 %
Total International Segment $ 134.3     $ 130.4     $ 3.9     3.0   %   7.2   %   (10.8 ) %   6.6 %
 
See footnote descriptions below Table 1 – B. 





Table 1–B: COMPONENTS OF REVENUES CHANGE IN DOLLARS (UNAUDITED)

(In millions)
  Three Months Ended

March 31, 2021
Organic Growth (1) $ 7.3    
Divestitures (135.0 )  
Foreign exchange (2) 10.7    
Total Change $ (117.0 )  

(1) Growth is the change in revenues excluding the impact of divestitures and foreign exchange.
(2) The comparisons at constant currency rates (foreign exchange) reflect comparative local currency balances at prior period’s foreign exchange rates. Stericycle calculated these percentages by taking current period reported Revenues less the respective prior period reported Revenues, divided by the prior period reported Revenues, all at the respective prior period’s foreign exchange rates. This measure provides information on the change in Revenues assuming that foreign currency exchange rates have not changed between the prior and the current period. Management believes the use of this measure aids in the understanding of changes in Revenues without the impact of foreign currency.
(3) In the first quarter of 2021, we updated our service lines to include Communication Solutions (formally part of CRS) in RWCS. This reclassification was driven by the divestiture of the Company’s global product recall business (Expert Solutions) in December of 2020 and the remaining Communication Solutions service line synergies with the Company’s RWCS customers. For 2020 periods presented, amounts have been recast to reflect this change.





RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES (UNAUDITED)

Table 2-A: THREE MONTHS ENDED MARCH 31, 2021 and 2020

(In millions, except per share data)
  Three Months Ended March 31, 2021
  Gross Profit   Selling,

General and Administrative

Expenses
  Income from Operations   Net Income

Attributable to Common

Shareholders (d)
  Diluted Earnings

Per Share
U.S. GAAP Financial Measures $ 261.4     $ 202.3     $ 59.1     $ 26.1     $ 0.28  
Adjustments:                  
ERP Implementation (1)     (17.9 )   17.9     13.3     0.14  
Intangible Amortization (2)     (29.8 )   29.8     23.1     0.25  
Divestitures (including Divestiture Losses (Gains), net) (3)     (1.2 )   1.2     0.9     0.02  
Litigation, Settlements and Regulatory Compliance (4)     (2.0 )   2.0     1.5     0.02  
Asset Impairments (5)                  
Other (6)                  
U.S. CARES Act (7)                  
Total Adjustments     (50.9 )   50.9     38.8     0.43  
Adjusted Financial Measures 

(a)
$ 261.4     $ 151.4     $ 110.0     $ 64.9     $ 0.71  
Depreciation (b)         25.2          
Adjusted EBITDA 

(c)
        $ 135.2          

(In millions, except per share data)
  Three Months Ended March 31, 2020
  Gross Profit   Selling,

General and Administrative

Expenses
  (Loss) Income from Operations   Net (Loss)

Income

Attributable to Common

Shareholders (d)
  Diluted (Loss) Earnings

Per Share
U.S. GAAP Financial Measures $ 286.6     $ 258.7     $ (30.4 )   $ (20.1 )   $ (0.22 )
Adjustments:                  
ERP Implementation (1)     (18.0 )   18.0     13.4     0.15  
Intangible Amortization (2)     (31.9 )   31.9     24.0     0.26  
Divestitures (including Divestiture Losses (Gains), net) (3)     (3.0 )   61.3     59.1     0.65  
Litigation, Settlements and Regulatory Compliance (4)     (4.4 )   4.4     3.3     0.04  
Asset Impairments (5)     (4.0 )   4.0     2.9     0.03  
Other (6)     (4.6 )   4.6     3.9     0.04  
U.S. CARES Act (7)             (39.4 )   (0.43 )
Total Adjustments     (65.9 )   124.2     67.2     0.74  
Adjusted Financial Measures 

(a)
$ 286.6     $ 192.8     $ 93.8     $ 47.1     $ 0.52  
Depreciation (b)         27.4          
Adjusted EBITDA 

(c)
        $ 121.2          

(In millions, except per share data)
  First Quarter 2021 Change Compared to First Quarter 2020
  Gross Profit   Selling,

General and Administrative Expenses
  Income (Loss) from Operations   Net Income (Loss)

Attributable to Common Shareholders (d)
  Diluted Earnings (Loss)

Per Share
U.S. GAAP Financial Measures $ (25.2 )   $ (56.4 )   $ 89.5     $ 46.2     $ 0.50  
Adjustments:                  
ERP Implementation     0.1     (0.1 )   (0.1 )   (0.01 )
Intangible Amortization     2.1     (2.1 )   (0.9 )   (0.01 )
Divestitures (including Divestiture Losses (Gains), net)     1.8     (60.1 )   (58.2 )   (0.63 )
Litigation, Settlements and Regulatory Compliance     2.4     (2.4 )   (1.8 )   (0.02 )
Asset Impairments     4.0     (4.0 )   (2.9 )   (0.03 )
Other     4.6     (4.6 )   (3.9 )   (0.04 )
U.S. CARES Act             39.4     0.43  
Total Adjustments     15.0     (73.3 )   (28.4 )   (0.31 )
Adjusted Financial Measures $ (25.2 )   $ (41.4 )   $ 16.2     $ 17.8     $ 0.19  
Depreciation         (2.2 )        
Adjusted EBITDA         $ 14.0          

The following table provides adjustments to Income (Loss) from Operations categorized as follows:

(In millions)
  Three Months Ended March 31,
  2021   2020
Non-Cash Related $ 0.3     $ 52.1  
Cash Related 20.8     40.2  
Intangible Amortization 29.8     31.9  
Total $ 50.9     $ 124.2  

Non-cash related adjustments include the following:

(In millions)
  Three Months Ended March 31, 2021
  Depreciation and Impairments of Property, Plant and Equipment   Impairments of Intangibles   Divestiture Losses (Gains), net   Total
Adjustments:              
ERP Implementation (1) (b) $ 0.3     $     $     $ 0.3  
Divestiture Losses (Gains), net (3)              
Asset Impairments (5)              
Total Non-Cash Charges $ 0.3     $     $ —      $ 0.3  

(In millions)
  Three Months Ended March 31, 2020
  Depreciation and Impairments of Property, Plant and Equipment   Impairments of Intangibles   Divestiture Losses (Gains), net   Total
Adjustments:              
ERP Implementation (1) (b) $ 0.6     $     $     $ 0.6  
Divestiture Losses (Gains), net (3)         47.5     47.5  
Asset Impairments (5)     4.0         4.0  
Total Non-Cash Charges $ 0.6     $ 4.0     $ 47.5     $ 52.1  

U.S. GAAP results for the three months ended March 31, 2021 and 2020 include:


(1)
 ERP Implementation: In 2021, Selling, General, and Administrative expenses (“SG&A”) includes $17.9 million of expenses related to our ERP implementation, of which $11.6 million related to consulting and professional fees, $3.1 million related to software usage/maintenance fees, $1.9 million related to internal costs, and $1.3 million of other related costs. In 2020, SG&A includes $18.0 million of expenses related to our ERP implementation, of which $10.4 million related to consulting and professional fees, $2.6 million related to software usage/maintenance fees, $3.6 million related to internal costs, and $1.4 million of other related costs.


(2)
 Intangible Amortization: Intangible amortization expense from acquisitions.


(3)
 Divestitures (including Divestiture (Gains) Losses, net): 2020 includes a $58.3 million impairment related to the divestiture of the Domestic Environmental Solutions business (inclusive of $10.8 million of related deal costs). SG&A in 2021 and 2020 includes consulting and professional fees associated with our Portfolio Optimization/Rationalization efforts of $1.2 million and $3.0 million, respectively.


(4)

 
Litigation, Settlements, and Regulatory Compliance: In 2021 and 2020, SG&A includes $2.0 million and $4.4 million, respectively, of primarily consulting and professional fees for certain litigation, settlement and regulatory compliance matters.


(5)
 Asset Impairments: In 2020, SG&A includes $4.0 million of non-cash impairment charges related to intangible assets as a result of discontinuation of a certain service line in North America.


(6)
 Other: In 2020, SG&A includes $4.6 million, of consulting and professional fees related to internal control remediation activities. Other expense, net includes a foreign exchange loss of $0.4 million related to the re-measurement of net monetary assets held in Argentina prior to divestiture in August of 2020, as a result of its designation as a highly inflationary economy.


(7)

U.S. CARES Act: In 2020, we recognized a $39.4 million tax benefit related to the U.S. CARES Act associated with our ability to carryback net operating losses to prior years that had higher tax rates.


(a)
 The Non-GAAP financial measures contained in this press release are reconciled to the most comparable measures calculated in accordance with U.S. GAAP in the schedules attached to this release.  Management believes the Non-GAAP financial measures are useful measures of Stericycle’s performance because they provide additional information about Stericycle’s operations and exclude certain adjusting items, allowing better evaluation of underlying business performance and better period-to-period comparability.  The Non-GAAP financial measures contained in this press release may not be calculated in the same manner as certain other Non-GAAP financial measures used solely to evaluate management’s performance for incentive compensation purposes. All Non-GAAP financial measures are intended to supplement the applicable U.S. GAAP measures and should not be considered in isolation from, or a replacement for, financial measures prepared in accordance with U.S. GAAP and may not be comparable to or calculated in the same manner as Non-GAAP financial measures published by other companies.


(b)
 Three months ended March 31, 2021 and 2020 exclude depreciation charges of $0.3 million and $0.6 million, respectively, that are included in ERP Implementation.


(c)
 Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (Adjusted EBITDA) is Income (loss) from operations excluding certain adjusting items, Depreciation and Intangible Amortization.


(


d)
 Under the Net Income (Loss) Attributable to Common Shareholders column, adjustments are shown net of tax in aggregate of $12.1 million and $57.3 million for the three months ended March 31, 2021 and 2020, respectively, based on applying the statutory tax rate for the jurisdictions in which the adjustment occurred or, by adjusting the tax effect to consider the impact of applying an annual effective tax rate on an interim basis. For purposes of reconciling adjusted diluted earnings per share with respect to taxes period-over-period, the company utilizes a “rate approach” to highlight the impact of the adjusted tax rate. It is computed by multiplying the prior period adjusted rate by the current period adjusted income before taxes to determine the expected tax expense. Such expected tax expense is then compared to actual tax expense. Expected tax in excess of actual tax variance is favorable; actual tax in excess of expected tax variance is unfavorable. The variance divided by diluted shares outstanding at the end of the period yields the impact on earnings per share. Management believes the use of this measure best aids in explaining the impact of a changing tax rate.